var title_f18_26_18848="Epidermal cysts on eyelid";
var content_f18_26_18848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidermal inclusion cysts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows epidermal inclusion cysts on the upper and lower eyelids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kersten, RC(Ed), Basic and clinical science courses section 7: Orbit, eyelids, and lacrimal system. American Academy of Ophthalmology, San Francisco 2002. Copyright &copy; 2002 American Academy of Ophthalmology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18848=[""].join("\n");
var outline_f18_26_18848=null;
var title_f18_26_18849="Calculator: Endotracheal tube size for children (Age 1 to 8 years)";
var content_f18_26_18849=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"    <tr>",
"     <td bgcolor=\"#eeeeee\" width=\"1%\">",
"      <br/>",
"     </td>",
"     <td align=\"left\" bgcolor=\"#eeeeee\">",
"      <span class=\"medCalcFontTitleBox\">",
"       Calculator: Endotracheal tube size for children (Age 1 to 8 years)",
"      </span>",
"     </td>",
"    </tr>",
"   </table>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <form action=\"\" id=\"PediatricETTubeSize_form\" name=\"PediatricETTubeSize_form\" onkeydown=\"clrResults();\" onkeyup=\"PediatricETTubeSize_fx();\" onsubmit=\"return false;\">",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         UncuffedEndotrachealTubeSize = 4 + (Age / 4)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         CuffedEndotrachealTubeSize = 3.5 + (Age / 4)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Age",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Age_param\" onblur=\"PediatricETTubeSize_fx(); minMaxCheck();\" onchange=\"PediatricETTubeSize_fx();\" size=\"5\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"PediatricETTubeSize_fx();\" style=\"width:105px;\">",
"             <option value=\"0.0833334|0|mo\">",
"              mo",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|yr\">",
"              yr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Uncuffed Endotracheal Tube Size",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Uncuffed_Endotracheal_Tube_Size_param\" onfocus=\"blur();\" size=\"5\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               mm (ID)",
"              </span>",
"             </span>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Cuffed Endotracheal Tube Size",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Cuffed_Endotracheal_Tube_Size_param\" onfocus=\"blur();\" size=\"5\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               mm (ID)",
"              </span>",
"             </span>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            <br/>",
"            <center>",
"             <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"            </center>",
"            <br/>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"   </form>",
"   <span class=\"medCalcFontOneBold\">",
"    Notes",
"   </span>",
"   <ul class=\"medCalcFontOne\">",
"    <li>",
"     Select an uncuffed tube with an internal diameter of 3.5 mm for infants up to 1 year of age.",
"    </li>",
"    <li>",
"     A cuffed ETT with an internal diameter of 3.0 mm may be used for infants more than 3.5 kg. and  &lt;1 year.",
"    </li>",
"    <li>",
"     ID stands for internal diameter. For patients 2 years and older, the age parameter is rounded to provide an endotracheal tube size that is likely to pass through the vocal cords and have a tight enough seal for ventilation (uncuffed endotracheal tube) or to allow for ventilation after cuff inflation (cuffed endotracheal tube).",
"    </li>",
"    <li>",
"     The cuffed tube equation is appropriate for low profile, thin walled cuffed endotracheal tubes.",
"    </li>",
"    <li>",
"     As opposed to the cuffed endotracheal tube calculator above which applies to thin-walled low pressure cuffed endotracheal tubes, when using a regular cuffed endotracheal tube, select a tube one FULL size smaller than that determined by the uncuffed endotracheal tube formula.",
"    </li>",
"    <li>",
"     Additional tubes one half size larger and one half size smaller than calculated should also be available during endotracheal intubation attempts regardless of whether an uncuffed or cuffed endotracheal tube is used.",
"    </li>",
"   </ul>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <span class=\"medCalcFontRef\">",
"    <b>",
"     References",
"    </b>",
"   </span>",
"   <ol>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      King BR, Baker MD, Braitman LE, et. al. Endotracheal tube selection in children: a comparison of four methods.",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      . 1993 Mar;22(3):530-4.",
"     </span>",
"    </li>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Khine HH, Corddry DH, Kettrick RG, et. al. Comparison of cuffed and uncuffed endotracheal tubes in young children during general anesthesia.",
"      <i>",
"       Anesthesiology",
"      </i>",
"      . 1997 Mar;86(3):627-31; discussion 27A.",
"     </span>",
"    </li>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Wheeler, M, Cote, CJ, Todres, ID. The pediatric airway. In: Cote C, Lerman J, Todres ID (Eds).",
"      <i>",
"       A Practice of Anesthesia for Infants and Children, 4th ed",
"      </i>",
"      . Saunders-Elsevier, Philadelphia 2009. p.237.",
"     </span>",
"    </li>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Kleinman ME, de Caen AR, Chameides L, et.al. Pediatric basic and advanced life support: 2010 International  Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.",
"      <i>",
"       Pediatrics",
"      </i>",
"      . 2010 Nov;126(5):e1261-318.",
"     </span>",
"    </li>",
"   </ol>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <div id=\"calc_hints\">",
"    <span class=\"medCalcFontOne\">",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18849=[" ",
"",
"var currenttimeout;",
"",
"function PediatricETTubeSize_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.PediatricETTubeSize_form){",
"",
"doCalc = true;",
"",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"",
"if ((Age - Math.floor(Age)) >= 0.5){ Round_Age = Math.floor(Age) + 1; } else { Round_Age = Math.floor(Age); };",
"",
"if (doCalc){",
"",
"if (Round_Age == 1){ Uncuffed_Endotracheal_Tube_Size_param.value = '4.0'; }; ",
"if (Round_Age == 2){ Uncuffed_Endotracheal_Tube_Size_param.value = '4.5'; Cuffed_Endotracheal_Tube_Size_param.value = '4.0'; }; ",
"if (Age < 2){ Cuffed_Endotracheal_Tube_Size_param.value = '3.5'; }; ",
"if (Round_Age == 3){ Uncuffed_Endotracheal_Tube_Size_param.value = '5.0'; Cuffed_Endotracheal_Tube_Size_param.value = '4.0'; }; ",
"if (Round_Age == 4){ Uncuffed_Endotracheal_Tube_Size_param.value = '5.0'; Cuffed_Endotracheal_Tube_Size_param.value = '4.5'; }; ",
"if (Round_Age == 5){ Uncuffed_Endotracheal_Tube_Size_param.value = '5.0'; Cuffed_Endotracheal_Tube_Size_param.value = '4.5'; }; ",
"if (Round_Age == 6){ Uncuffed_Endotracheal_Tube_Size_param.value = '5.5'; Cuffed_Endotracheal_Tube_Size_param.value = '5.0'; }; ",
"if (Round_Age == 7){ Uncuffed_Endotracheal_Tube_Size_param.value = '6.0'; Cuffed_Endotracheal_Tube_Size_param.value = '5.0'; }; ",
"if (Round_Age == 8){ Uncuffed_Endotracheal_Tube_Size_param.value = '6.0'; Cuffed_Endotracheal_Tube_Size_param.value = '5.5'; }; ",
"",
"}",
"}}",
"",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PediatricETTubeSize_form){",
"",
"if (Age_param.value && Age < 1) {",
"Age = 0;",
"Age_param.value = '';",
"clrResults();",
"doCalc = false;",
"alert('The minimum value for Age is 1 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.');",
"}",
"",
"if (Age_param.value && Age > 8) {",
"Age_param.value = '';",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert('The maximum value for Age is 8 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.');",
"}",
"",
"}}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PediatricETTubeSize_form){",
"",
"Uncuffed_Endotracheal_Tube_Size_param.value = '';",
"Cuffed_Endotracheal_Tube_Size_param.value = '';",
"",
"}}",
"",
""].join("\n");
var outline_f18_26_18849=null;
var title_f18_26_18850="Leukocytoclastic vasculitis - bullous";
var content_f18_26_18850=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous leukocytoclastic vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicles overlying purpuric macules are present on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18850=[""].join("\n");
var outline_f18_26_18850=null;
var title_f18_26_18851="Liposomal bupivacaine: Patient drug information";
var content_f18_26_18851=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Liposomal bupivacaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/52/27460?source=see_link\">",
"     see \"Liposomal bupivacaine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14187699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exparel&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14189996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3731796",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain at the surgery site.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14189995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701660",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bupivacaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14190000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14190001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14190003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14189998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F14190004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14190005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83361 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18851=[""].join("\n");
var outline_f18_26_18851=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14187699\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14189996\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14189995\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190000\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190001\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190003\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14189998\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190004\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14190005\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/52/27460?source=related_link\">",
"      Liposomal bupivacaine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_26_18852="Cutaneous horn on the cheek";
var content_f18_26_18852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous horn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A horn-like keratotic projection is present on the skin. Lesions such as squamous cell carcinoma, viral warts, actinic keratoses, and seborrheic keratoses may underly cutaneous horns.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18852=[""].join("\n");
var outline_f18_26_18852=null;
var title_f18_26_18853="Drug treatment of hypertensive emergencies";
var content_f18_26_18853=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug treatment of hypertensive emergencies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/26/18853/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18853/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/26/18853/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18853/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/26/18853/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18853/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/26/18853/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hypertensive emergency is considered to be present when severe hypertension is associated with acute end-organ damage. Examples include malignant hypertension, with or without hypertensive encephalopathy, subarachnoid or intracerebral hemorrhage, acute pulmonary edema, aortic dissection, and rebound after withdrawal of antihypertensive medications. Immediate but careful reduction in blood pressure is indicated in these settings. However, an excessive hypotensive response is potentially dangerous, possibly leading to ischemic complications such as stroke, myocardial infarction or blindness in some cases. Thus, in patients who are severely hypertensive but asymptomatic, slower reductions in blood pressure should be provided with oral agents (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PARENTERAL DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of both parenteral and oral antihypertensive drugs can be used in these patients (",
"    <a class=\"graphic graphic_table graphicRef64066 graphicRef75865 \" href=\"UTD.htm?39/49/40733\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=see_link\">",
"     \"Treatment of specific hypertensive emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nitroprusside",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     Nitroprusside",
"    </a>",
"    dilates both arterioles and veins and is generally considered to be the most effective parenteral drug for most hypertensive emergencies. Nitroprusside, administered by intravenous infusion, begins to act within less than one minute and its effects disappear within 1 to 10 minutes, thereby minimizing the risk of hypotension. Constant monitoring of the blood pressure is required. Nitroprusside and other nitrovasodilators (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ) that provide nitric oxide appear to induce vasodilatation via generation of cyclic GMP which then activates calcium-sensitive potassium channels in the cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major limitation to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    is its metabolism to cyanide, possibly leading to the development of cyanide or rarely thiocyanate toxicity that may be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/5\">",
"     5",
"    </a>",
"    ]. This problem, which is manifested by clinical deterioration, altered mental status, and lactic acidosis, can be minimized by using the lowest possible dose and by careful patient monitoring. Treatment for a prolonged period (&gt;24 to 48 hours), underlying renal insufficiency, and the use of doses that exceed the capacity of the body to detoxify cyanide (more than 2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min) increase the risk of cyanide accumulation. The current FDA recommendation is that maximum doses of 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute should never be given for more than 10 minutes. An infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    can be used in affected patients to provide a sulfur donor to detoxify cyanide into thiocyanate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    is 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute. This can be increased as necessary to a maximum dose of 8 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute, although use of these higher doses should generally be avoided or limited to a maximum duration of 10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/5\">",
"     5",
"    </a>",
"    ]. Nitroprusside should not be given to pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    is also administered by intravenous infusion and is similar in action and pharmacokinetics to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    except that it produces relatively greater venodilation than arteriolar dilation. It may be most useful in patients with symptomatic coronary disease and in those with hypertension following coronary bypass.",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is 5",
"    <span class=\"nowrap\">",
"     mcg/min,",
"    </span>",
"    which can be increased as necessary to a maximum of 100",
"    <span class=\"nowrap\">",
"     mcg/min.",
"    </span>",
"    The onset of action is 2 to 5 minutes, while the duration of action is 5 to 10 minutes. Headache (due to direct vasodilation) and tachycardia (resulting from reflex sympathetic activation) are the primary side effects. Cyanide accumulation does not occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clevidipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/25/39317?source=see_link\">",
"     Clevidipine",
"    </a>",
"    is a short-acting dihydropyridine calcium channel blocker that has been approved for intravenous use to treat severe hypertension. It reduces blood pressure without affecting cardiac filling pressures or causing reflex tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Its role in the treatment of hypertensive emergencies compared to other short-acting drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , has not been defined. The initial dose is 1",
"    <span class=\"nowrap\">",
"     mg/hour,",
"    </span>",
"    which can be increased as necessary to a maximum of 21",
"    <span class=\"nowrap\">",
"     mg/hour.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nicardipine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     Nicardipine",
"    </a>",
"    is a dihydropyridine calcium channel blocker (like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) that can be given as an intravenous infusion. The initial dose is 5",
"    <span class=\"nowrap\">",
"     mg/h",
"    </span>",
"    and can be increased to a maximum of 15",
"    <span class=\"nowrap\">",
"     mg/h.",
"    </span>",
"    Initial experience with nicardipine has been favorable when compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/8\">",
"     8",
"    </a>",
"    ]. The major limitation is a longer half-time, which precludes rapid titration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fenoldopam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=see_link\">",
"     Fenoldopam",
"    </a>",
"    is a peripheral dopamine-1 receptor agonist, and unlike other parenteral antihypertensive agents, maintains or increases renal perfusion while it lowers BP [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/9\">",
"     9",
"    </a>",
"    ]. It maintains most of its efficacy for 48 hours of constant rate infusion without rebound hypertension when discontinued. Fenoldopam can be safely used in all hypertensive emergencies, and may be particularly beneficial in patients with renal insufficiency. After a starting dose of 0.1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min, the dose is titrated at 15 min intervals, depending on the BP response. Fenoldopam should be used cautiously or not at all in patients with glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Labetalol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    is a combined beta-adrenergic and alpha-adrenergic blocker. Its rapid onset of action (5 minutes or less) makes it useful in the treatment of hypertensive emergencies. Labetalol is safe in patients with active coronary disease, since it does not increase the heart rate.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    should generally be avoided in patients with asthma, chronic obstructive lung disease, heart failure, bradycardia, or greater than first-degree heart block. In addition, labetalol should not be used without prior adequate alpha-blockade in patients with hyperadrenergic states, such as pheochromocytoma and methamphetamine overdose, since unopposed, inadequately blocked alpha-adrenergic activity can lead to a further rise in blood pressure if beta blockade is not complete.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    can be given as an intravenous bolus or infusion. The bolus dose is 20 mg initially, followed by 20 to 80 mg every 10 minutes to a total dose of 300 mg. The infusion rate is 0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Esmolol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     Esmolol",
"    </a>",
"    , a relatively cardioselective beta blocker, is rapidly metabolized by blood esterases and has a short (about 9 minutes) half-life and total duration of action (about 30 minutes). Its effects begin almost immediately, and it has found particular use during anesthesia to prevent postintubation hemodynamic perturbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hydralazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     Hydralazine",
"    </a>",
"    is a direct arteriolar vasodilator with little or no effect on the venous circulation. Thus, precautions are needed in patients with underlying coronary disease or an aortic dissection, and a beta-blocker should be given concurrently to minimize reflex sympathetic stimulation. The hypotensive response to hydralazine is less predictable than that seen with other parenteral agents and its current use is primarily limited to pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     Hydralazine",
"    </a>",
"    can be given as an intravenous bolus. The initial dose is 10 mg, with the maximum dose being 20 mg. The fall in blood pressure begins within 10 to 30 minutes and lasts 2 to 4 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Enalaprilat",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=see_link\">",
"     Enalaprilat",
"    </a>",
"    is an intravenous preparation of the active form of the angiotensin converting enzyme (ACE) inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    . The response to enalaprilat is variable and not predictable, a reflection of the variable plasma volume and plasma renin activity in patients with a hypertensive emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/10\">",
"     10",
"    </a>",
"    ]. As an example, hypovolemic patients with a high plasma renin activity may have an excessive hypotensive response. In addition, ACE inhibitors are contraindicated in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual initial dose is 1.25 mg. As much as 5 mg may be given every six hours as necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18853/abstract/10\">",
"     10",
"    </a>",
"    ]. The onset of action begins in 15 minutes but the peak effect may not be seen for four hours. The duration of action ranges from 12 to 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Phentolamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     Phentolamine",
"    </a>",
"    is an alpha-adrenergic blocker, the use of which is limited to the treatment of severe hypertension due to increased catecholamine activity. Examples include pheochromocytoma and tyramine ingestion in a patient being treated with a monoamine oxidase inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link\">",
"     \"Treatment of pheochromocytoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"     Phentolamine",
"    </a>",
"    is given as an intravenous bolus. The usual dose is 5 to 10 mg every 5 to 15 minutes as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ORAL DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral antihypertensive agents lower the blood pressure more slowly than parenteral drugs. Thus, they are primarily used when parenteral agents are not available or when there is severe hypertension without serious acute end-organ damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28246?source=see_link\">",
"     \"Management of severe asymptomatic hypertension (hypertensive urgencies)\"",
"    </a>",
"    .) for a discussion of this issue, and (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27539?source=see_link\">",
"       \"Patient information: High blood pressure emergencies (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hypertensive emergency is defined as severe hypertension that is associated with acute end-organ damage. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate but careful reduction in blood pressure is indicated in hypertensive emergencies; an excessive hypotensive response may lead to ischemic complications. A number of both parenteral and oral antihypertensive drugs may be used. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Parenteral drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parenteral drugs include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , calcium channel blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=see_link\">",
"       fenoldopam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=see_link\">",
"       enalaprilat",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"       phentolamine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Parenteral drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients who are severely hypertensive but asymptomatic, slower reductions in blood pressure should be provided with oral agents. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Oral drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/1\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/2\">",
"      Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000; 356:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/3\">",
"      Rosei EA, Salvetti M, Farsang C. European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies. J Hypertens 2006; 24:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/4\">",
"      Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 1994; 91:7583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/5\">",
"      Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet 1984; 9:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/6\">",
"      Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs 2008; 68:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/7\">",
"      Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 2008; 107:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/8\">",
"      Neutel JM, Smith DH, Wallin D, et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens 1994; 7:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/9\">",
"      Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001; 345:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18853/abstract/10\">",
"      Hirschl MM, Binder M, Bur A, et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 1995; 155:2217.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3840 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18853=[""].join("\n");
var outline_f18_26_18853=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PARENTERAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nitroprusside",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clevidipine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nicardipine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fenoldopam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Labetalol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Esmolol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hydralazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Enalaprilat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Phentolamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ORAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3840\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3840|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/2/2093\" title=\"table 1A\">",
"      Drugs for HTV emergencies A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/53/10076\" title=\"table 1B\">",
"      Drugs for HTV emergencies B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28246?source=related_link\">",
"      Management of severe asymptomatic hypertension (hypertensive urgencies)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27539?source=related_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=related_link\">",
"      Treatment of specific hypertensive emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_26_18854="Keratosis pilaris dark skin";
var content_f18_26_18854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratosis pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Keratosis pilaris. Multiple follicularly-based hyperpigmented papules are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18854=[""].join("\n");
var outline_f18_26_18854=null;
var title_f18_26_18855="Insulin NPH and insulin regular: Drug information";
var content_f18_26_18855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin NPH and insulin regular: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6341?source=see_link\">",
"    see \"Insulin NPH and insulin regular: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/46/6886?source=see_link\">",
"    see \"Insulin NPH and insulin regular: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2137923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumuLIN&reg; 70/30;",
"     </li>",
"     <li>",
"      NovoLIN&reg; 70/30",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2186441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humulin&reg; 20/80;",
"     </li>",
"     <li>",
"      Humulin&reg; 70/30;",
"     </li>",
"     <li>",
"      Novolin&reg; ge 30/70;",
"     </li>",
"     <li>",
"      Novolin&reg; ge 40/60;",
"     </li>",
"     <li>",
"      Novolin&reg; ge 50/50",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2136122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2137946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Insulin NPH is an intermediate-acting insulin and regular insulin is a short-acting insulin administered by SubQ injection. When compared to insulin NPH, the combination product (insulin NPH and insulin regular) has a shorter onset of action and a similar duration of action. With combination insulin products, the proportion of short-acting to long-acting insulin is fixed; basal vs prandial dose adjustments cannot be made. Fixed-ratio insulins (such as insulin NPH and insulin regular combination) are typically administered as 2 daily doses with each dose intended to cover two meals and a snack. Because of variability in the peak effect and individual patient variability in activities, meals, etc, it may be more difficult to achieve complete glycemic control using fixed combinations of insulins; frequent monitoring and close medical supervision may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of different insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined.",
"     </b>",
"     Insulin NPH and insulin regular combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing of combination insulin products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate-acting (eg, NPH) or a long-acting form of insulin (in 1-2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting or short-acting form of insulin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 2:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate):",
"     <b>",
"      Note:",
"     </b>",
"     Insulin NPH and insulin regular combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing of combination insulin products. Dosage must be carefully adjusted.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2137945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/46/6886?source=see_link\">",
"      see \"Insulin NPH and insulin regular: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ: Children and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2329481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8102913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8102914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumuLIN&reg; 70/30: Insulin NPH suspension 70% [intermediate acting] and insulin regular solution 30% [short acting]: 100 units/mL (3 mL) [prefilled pen, vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HumuLIN&reg; 70/30: Insulin NPH suspension 70% [intermediate acting] and insulin regular solution 30% [short acting]: 100 units/mL (10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     NovoLIN&reg; 70/30: Insulin NPH suspension 70% [intermediate acting] and insulin regular solution 30% [short acting]: 100 units/mL  (10 mL) [vial]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F6256323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Humulin&reg; 20/80: Insulin regular solution 20% [short acting] and insulin NPH suspension 80% [intermediate acting]: 100 units/mL (3 mL) [PenFill&reg; prefilled cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Novolin&reg; ge 30/70: Insulin regular solution 30% [short acting] and insulin NPH suspension 70% [intermediate acting]: 100 units/mL (3 mL) [prefilled syringe or PenFill&reg; prefilled cartridge]; (10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Novolin&reg; ge 40/60: Insulin regular solution 40% [short acting] and insulin NPH suspension 60% [intermediate acting]: 100 units/mL (3 mL) [PenFill&reg; prefilled cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Novolin&reg; ge 50/50: Insulin regular solution 50% [short acting] and insulin NPH suspension 50% [intermediate acting]: 100 units/mL (3 mL) [PenFill&reg; prefilled cartridge]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2344735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2137947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ administration: In order to properly resuspend the insulin, vials should be carefully shaken or rolled several times, prefilled pens should be rolled between the palms ten times and inverted 180&deg; ten times, and cartridges should be inverted 180&deg; at least ten times.  Properly resuspended insulin should look uniformly cloudy or milky; do not use if any white insulin substance remains at the bottom of the container, if any clumps are present, if the insulin remains clear after adequate mixing, or if white particles are stuck to the bottom or wall of the container.  Cold injections should be avoided. Insulin NPH and insulin regular combination products should be administered within 30 minutes before a meal; typically given once- or twice daily.  SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites. Do not mix with any other insulin formulation.  Do not dilute combination product (insulin NPH and insulin regular) contained in a cartridge or prefilled pen. Combination insulin products are not recommended for use in an external SubQ insulin infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2137936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     A universal sterile diluent, Sterile Diluent for Humalog&reg;, Humulin&reg; N, Humulin&reg; R, Humulin&reg; 70/30, and Humulin&reg; R U-500, is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin glulisine, insulin lispro.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2137925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8102905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gestational diabetes mellitus (GDM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2137921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumuLIN&reg; 70/30 may be confused with HumaLOG&reg; Mix 75/25, HumuLIN&reg; R, NovoLIN&reg; 70/30, NovoLOG&reg; Mix 70/30",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NovoLIN&reg; 70/30 may be confused with HumaLOG&reg; Mix 75/25, HumuLIN&reg; 70/30, HumuLIN&reg; R, NovoLIN&reg; R, and NovoLOG&reg; Mix 70/30",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8102907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2138086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; during episodes of hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2137930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death.  Insulin requirements may be altered during illness, emotional disturbances, or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death.  Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Insulin NPH and insulin regular combination products are",
"     <b>",
"      NOT",
"     </b>",
"     intended for I.V. or I.M. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases.  Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- [insulin NPH and insulin regular] or long-acting insulin or via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration.  Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals.  Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control.  Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control.  Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8102910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8102911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2137927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2137929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8102915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (HumuLIN 70/30 Pen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (70-30) 100 units/mL (3 mL): $57.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (HumuLIN 70/30 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (70-30) 100 units/mL (10 mL): $21.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (NovoLIN 70/30 ReliOn Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (70-30) 100 units/mL (10 mL): $90.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (NovoLIN 70/30 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (70-30) 100 units/mL (10 mL): $90.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8102916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6258747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes mellitus (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actraphane HM (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, PH, SC, SD, SL, SN, TH, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Berlinsulin H 10 90 (DE);",
"     </li>",
"     <li>",
"      Berlinsulin H 20 80 (DE);",
"     </li>",
"     <li>",
"      Berlinsulin H 30 70 (DE);",
"     </li>",
"     <li>",
"      Berlinsulin H 40 60 (DE);",
"     </li>",
"     <li>",
"      Gensulin M30 (TH);",
"     </li>",
"     <li>",
"      Huminsulin \"Lilly\" Long (AT);",
"     </li>",
"     <li>",
"      Huminsulin Profil I (CH, DE);",
"     </li>",
"     <li>",
"      Huminsulin Profil II (CH, DE);",
"     </li>",
"     <li>",
"      Huminsulin Profil III (CH, DE);",
"     </li>",
"     <li>",
"      Huminsulin Profil IV (CH, DE);",
"     </li>",
"     <li>",
"      Humulin 10 90 (IT, MY);",
"     </li>",
"     <li>",
"      Humulin 20 80 (AU, IT, MY);",
"     </li>",
"     <li>",
"      Humulin 30 70 (AU, CR, DO, GT, HN, IT, MX, MY, NI, PA, SE, SV);",
"     </li>",
"     <li>",
"      Humulin 40 60 (IT, MY);",
"     </li>",
"     <li>",
"      Humulin 50/50 (AU);",
"     </li>",
"     <li>",
"      Humulin 60 40 (KP, TH);",
"     </li>",
"     <li>",
"      Humulin 70/30 (BB, BM, BS, BZ, CL, CO, GY, JM, NL, NZ, PE, SR, TT, VE);",
"     </li>",
"     <li>",
"      Humulin 70N/30R (BR);",
"     </li>",
"     <li>",
"      Humulin 80 20 (TH);",
"     </li>",
"     <li>",
"      Humulin M1 (GB);",
"     </li>",
"     <li>",
"      Humulin M2 (GB);",
"     </li>",
"     <li>",
"      Humulin M3 (GB);",
"     </li>",
"     <li>",
"      Humulin M4 (GB);",
"     </li>",
"     <li>",
"      Humulina 30 70 (ES);",
"     </li>",
"     <li>",
"      Humuline 20 80 (BE);",
"     </li>",
"     <li>",
"      Humuline 30 70 (BE);",
"     </li>",
"     <li>",
"      Humuline 40 60 (BE);",
"     </li>",
"     <li>",
"      Insulin \"Novo Nordisk\" Mixtard HM 15 85 (AT);",
"     </li>",
"     <li>",
"      Insulin \"Novo Nordisk\" Mixtard HM 30 70 (AT);",
"     </li>",
"     <li>",
"      Insulin \"Novo Nordisk\" Mixtard HM 50 50 (AT);",
"     </li>",
"     <li>",
"      Insulin Actraphan HM (CH);",
"     </li>",
"     <li>",
"      Insulin Actraphane HM (HN);",
"     </li>",
"     <li>",
"      Insulin Actraphane HM 10 90 (DE);",
"     </li>",
"     <li>",
"      Insulin Actraphane HM 20 80 (DE);",
"     </li>",
"     <li>",
"      Insulin Actraphane HM 30 70 (DE);",
"     </li>",
"     <li>",
"      Insulin Actraphane HM 40 60 (DE);",
"     </li>",
"     <li>",
"      Insulin Actraphane HM 50 50 (DE);",
"     </li>",
"     <li>",
"      Insulin Hoechst-Komb 15 U-100 (CH);",
"     </li>",
"     <li>",
"      Insulin Hoechst-Komb 25 U-100 (CH);",
"     </li>",
"     <li>",
"      Insulin Hoechst-Komb 50 U-100 (CH);",
"     </li>",
"     <li>",
"      Insulin Mixtard 10 HM (CH);",
"     </li>",
"     <li>",
"      Insulin Mixtard 15 85 Human (IL);",
"     </li>",
"     <li>",
"      Insulin Mixtard 20 HM (CH);",
"     </li>",
"     <li>",
"      Insulin Mixtard 30 70 Human (DE);",
"     </li>",
"     <li>",
"      Insulin Mixtard 30 HM (CH, IL);",
"     </li>",
"     <li>",
"      Insulin Mixtard 40 HM (CH);",
"     </li>",
"     <li>",
"      Insulin Mixtard 50 50 HM (IL);",
"     </li>",
"     <li>",
"      Insulin Mixtard 50 50 Human (DE);",
"     </li>",
"     <li>",
"      Insulin Mixtard 50 HM (CH);",
"     </li>",
"     <li>",
"      Insulina Humulin 70/30 (AR, CN);",
"     </li>",
"     <li>",
"      Insuline Humaan (NL);",
"     </li>",
"     <li>",
"      Insuline Humuline 10 90 (NL);",
"     </li>",
"     <li>",
"      Insuline Humuline 20 80 (NL);",
"     </li>",
"     <li>",
"      Insuline Humuline 30 70 (NL);",
"     </li>",
"     <li>",
"      Insuline Humuline 40 60 (NL);",
"     </li>",
"     <li>",
"      Insuman 25 (DE);",
"     </li>",
"     <li>",
"      Insuman 50 (DE);",
"     </li>",
"     <li>",
"      Insuman Comb 15 (DE);",
"     </li>",
"     <li>",
"      Mixtard 15 85 (AU);",
"     </li>",
"     <li>",
"      Mixtard 30 70 (AU);",
"     </li>",
"     <li>",
"      Mixtard 30 HM (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Mixtard 30 Human (ID);",
"     </li>",
"     <li>",
"      Mixtard 50 50 (AU);",
"     </li>",
"     <li>",
"      Mixtard Human (KP);",
"     </li>",
"     <li>",
"      Mixtard Innolet (FR);",
"     </li>",
"     <li>",
"      Novolin 70/30 (MX);",
"     </li>",
"     <li>",
"      Orgasuline 30/70 (FR);",
"     </li>",
"     <li>",
"      Ransilun 30/70 (PH);",
"     </li>",
"     <li>",
"      Scilin M30 (HK, PH);",
"     </li>",
"     <li>",
"      Umuline Profil 10 (FR);",
"     </li>",
"     <li>",
"      Umuline Profil 20 (FR);",
"     </li>",
"     <li>",
"      Umuline Profil 30 (FR);",
"     </li>",
"     <li>",
"      Umuline Profil 40 (FR);",
"     </li>",
"     <li>",
"      Wosulin 30/70 (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2137937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin NPH and insulin regular is an intermediate-acting combination insulin product with a more rapid onset than that of insulin NPH alone.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2137939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 2-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Based on individual components:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Insulin regular: 0.8-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Insulin NPH: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/26/18855/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/26/18855/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/26/18855/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/26/18855/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/26/18855/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/26/18855/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9029 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18855=[""].join("\n");
var outline_f18_26_18855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137923\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186441\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136122\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137946\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137945\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2329481\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102913\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102914\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104228\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6256323\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2344735\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137947\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137936\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137925\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102905\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137921\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102907\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138086\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137930\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102910\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221043\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102911\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137927\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137929\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102915\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422164\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102916\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6258747\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869459\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137937\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137939\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9029\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9029|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6341?source=related_link\">",
"      Insulin NPH and insulin regular: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/46/6886?source=related_link\">",
"      Insulin NPH and insulin regular: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_26_18856="The use of inhaler devices in adults";
var content_f18_26_18856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The use of inhaler devices in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/26/18856/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18856/contributors\">",
"     William Bailey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18856/contributors\">",
"     Dean Hess, RRT, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/26/18856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18856/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/26/18856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18856/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/26/18856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaler devices are the major method for delivery of asthma medication, but their effectiveness can be compromised if the patient uses the inhaler device incorrectly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/1\">",
"     1",
"    </a>",
"    ]. The magnitude of this problem has been well documented; in several studies less than half of the patients used their inhaler correctly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/2-9\">",
"     2-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of inhaler devices by adults will be presented here. More general discussions of the delivery of inhaled medication and what patients need to know about their asthma are presented separately (",
"    <a class=\"graphic graphic_table graphicRef71527 \" href=\"UTD.htm?17/10/17581\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"     \"What do patients need to know about their asthma?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74579844\">",
"    <span class=\"h1\">",
"     TYPES OF INHALER DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaler devices are used to deliver a variety of inhaled medications, including beta-agonists, anticholinergics, and glucocorticoids. Two main types of inhaler devices are available, the pressurized metered dose inhaler (MDI) and the dry powder inhaler (DPI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85082029\">",
"    <span class=\"h2\">",
"     Metered dose inhalers with CFC and HFA",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDI devices consist of a pressurized canister, a metering valve and stem, and a mouthpiece actuator (",
"    <a class=\"graphic graphic_picture graphicRef62613 \" href=\"UTD.htm?37/43/38591\">",
"     picture 1",
"    </a>",
"    ). The pressurized canister contains the drug suspended in a mixture of propellants, surfactants, preservatives, flavoring agents, and dispersal agents. The propellant, which comprises about 80 percent of the aerosol, has traditionally been a chlorofluorocarbon (CFC). Following adoption of the Montreal protocol, an international agreement to ban CFCs, the CFC-free propellant hydrofluoroalkane (HFA)-133a has largely replaced CFC-containing devices [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/10-22\">",
"     10-22",
"    </a>",
"    ]. Inhalation from an HFA device has a different feel and taste compared with the old CFC devices. In particular the aerosol jet is softer and may feel as though less medication is being delivered. However, delivery of most aerosol medications to the lungs is comparable between HFA and CFC devices [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/19,23-25\">",
"     19,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few glucocorticoid-containing hydrofluoroalkane (HFA) MDIs actually deliver a greater proportion of the dose to the lungs than the comparable CFC MDI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. The deposition into the lungs appears to be related to the smaller particle size distribution of the HFA inhaler [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. This variance in drug delivery to the lungs makes it difficult to directly compare dosages when switching from one inhaled glucocorticoid preparation to another. Once a patient has stabilized on a new inhaler, the dose may need to be adjusted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85082036\">",
"    <span class=\"h2\">",
"     Dry powder inhalers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry powder inhalers (DPI) are breath-actuated devices that deliver micronized drug particles with a mass median aerodynamic diameter (MMAD) of less than 5 &micro;m, which usually are aggregated with carrier particles (such as lactose or glucose) of greater diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. Drug is delivered to the airways by the inhalation of air over a punctured capsule or blister [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/2,32,33\">",
"     2,32,33",
"    </a>",
"    ]. Inspiratory flow rates of 30 to 60",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    are required to disaggregate and aerosolize the drug when using a DPI device [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62570469\">",
"    <span class=\"h1\">",
"     SPACERS AND HOLDING CHAMBERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using a spacer or valved holding chamber with an MDI allows the velocity of particles to decrease before reaching the mouth, which decreases the amount of oropharyngeal deposition (",
"    <a class=\"graphic graphic_picture graphicRef58957 \" href=\"UTD.htm?22/4/22607\">",
"     picture 2",
"    </a>",
"    ). Use of a valved holding chamber also allows sequential actuation and inhalation as the aerosol is retained in the chamber after actuation of the MDI. We typically prescribe a valved holding chamber for patients with difficulty coordinating inhalation actuation and inhalation and for those using MDIs containing glucocorticoids, especially if the dose is in the medium to high range. Spacers are less expensive than valved holding chambers and may be a better option in resource-limited settings, although they do not allow for sequential actuation and inhalation. Spacers and valved holding chambers require a prescription from a clinician.",
"   </p>",
"   <p>",
"    A spacer is usually an open-ended tube or bag that is of sufficient volume to allow the aerosol plume from the MDI to expand and the propellant to evaporate. The spacer should be at least 100 to 700 mL in volume, and should provide a distance of 10 to 13 cm between the MDI nozzle and the mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/37\">",
"     37",
"    </a>",
"    ]. By dispersing the aerosol into the spacer, the individual medication droplets experience slight evaporative loss of the propellant, which decreases the droplet size and thereby decreases oral deposition of the aerosol. The spacer holds the medicine aerosol long enough for patients to inhale slowly and deeply (",
"    <a class=\"graphic graphic_picture graphicRef58957 \" href=\"UTD.htm?22/4/22607\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/38\">",
"     38",
"    </a>",
"    ]. Spacers can increase the bioavailability of inhaled medication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the dose can be lost or diluted if the patient exhales into the spacer prior to inhalation of the dose.",
"   </p>",
"   <p>",
"    The valved-holding chamber is a specialized spacer that incorporates a one-way valve between the chamber and the mouthpiece. This design permits sequential actuation and inhalation as the aerosol is retained in the chamber after actuation of the MDI. In addition, the valve prevents the exhaled breath from entering the chamber, so the aerosol medication is held in the chamber to allow a second or third inhalation. Commonly used valved holding chambers include rigid devices, such as the AeroChamber, and plastic collapsible holding chambers, such as the InspirEase bag (",
"    <a class=\"graphic graphic_picture graphicRef58957 \" href=\"UTD.htm?22/4/22607\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Despite the increasing variety and popularity of spacer devices, little information is available on their relative performance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/40\">",
"     40",
"    </a>",
"    ]. In general, larger sized spacers appear more effective than smaller ones, but proper technique remains important for obtaining optimal drug delivery (",
"    <a class=\"graphic graphic_table graphicRef74044 \" href=\"UTD.htm?35/53/36699\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55242 \" href=\"UTD.htm?24/52/25417\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMMON PROBLEMS WITH INHALER DEVICES",
"    </span>",
"   </p>",
"   <p>",
"    The main problems with the use of inhaler devices, such as metered dose and dry powder inhalers, are upper airway deposition and poor coordination between actuation and inhalation. A less common problem is that of an insufficient breath-hold after inhalation of the medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Upper airway deposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metered dose inhalers tend to spray out medication more quickly than the patient can inhale. In addition, some patients do not inhale long enough after actuation of the device. As a result, a substantial amount of the medication is deposited in the back of the throat or on the tongue. Oropharyngeal deposition results in inefficient medication delivery and, with inhaled glucocorticoids, may cause hoarseness and thrush. It has been estimated that, in most patients, only about 10 percent of the dose reaches the lungs, while 80 percent remains in the oropharynx, although this varies depending on the preparation and delivery device [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/3,26-28,43,44\">",
"     3,26-28,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of HFA MDIs may diminish oropharyngeal deposition as they tend to deliver a greater proportion of the actuated dose to the airways in the lungs and less to the oropharynx compared with CFC MDIs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/26-30\">",
"     26-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another way to address this problem is to add a spacer device or valved holding chamber, which can decrease the oral deposition of medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/3\">",
"     3",
"    </a>",
"    ]. In a study comparing HFA and CFC formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    with and without a valved holding chamber or large volume spacer, the valved holding chamber and spacer decreased oropharyngeal deposition from approximately 80 percent to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H62570469\">",
"     'Spacers and holding chambers'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Actuation-inhalation coordination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other major cause of inefficient delivery of inhaled medications is lack of coordination between actuation and inhalation. Alternatives to the traditional MDIs have been developed to overcome this problem:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A few MDI devices (eg, Maxair Autohaler) are actuated by the patient's intake of a breath, eliminating the need to coordinate inhalation and hand actuation. Preliminary studies suggested that these devices deliver the medication more efficiently [",
"      <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/1,45-49\">",
"       1,45-49",
"      </a>",
"      ]. In one study, patient timing errors were reduced by the breath-activated inhaler in novice volunteers from 32 percent to 6.5 percent and in experienced patients from 21.5 percent to 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/45\">",
"       45",
"      </a>",
"      ]. However, other studies have found that when patients use their inhaler properly, there are no differences in clinical outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/50-53\">",
"       50-53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dry powder inhalers (DPIs) that contain the medication in the form of dry powder are breath actuated. The force of the patient&rsquo;s inhalation draws the powder into the lungs (",
"      <a class=\"graphic graphic_picture graphicRef57922 \" href=\"UTD.htm?41/43/42675\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link&amp;anchor=H339674#H339674\">",
"       \"Delivery of inhaled medication in adults\", section on 'Dry powder inhalers (DPI)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62571105\">",
"    <span class=\"h2\">",
"     Insufficient breath-hold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual advice is for a 5 to 10 second breath-hold at the end of inhalation from either an MDI or a DPI. In support of this recommendation, a study examining the effect of breath-hold on drug delivery from HFA MDIs containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    found that lung deposition was reduced by 16 percent with a 1 second versus a 10 second breath-hold [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TEACHING INHALER USE SKILLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Asthma Education Program (NAEP) recommends that patients be taught inhaler use in the following manner [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The clinician should first demonstrate the steps on the checklist",
"     </li>",
"     <li>",
"      The patient then practices in front of the clinician so that errors may be corrected",
"     </li>",
"     <li>",
"      The patient's technique should be evaluated periodically, and corrections made as necessary",
"     </li>",
"     <li>",
"      Patients should be positively reinforced for correct inhaler technique",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At follow-up visits, the best way to assess if a patient uses the inhaler correctly is to observe the patient. There are a number of published checklists or criteria for correct use of the standard aerosolized MDI (",
"    <a class=\"graphic graphic_figure graphicRef55242 \" href=\"UTD.htm?24/52/25417\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74044 \" href=\"UTD.htm?35/53/36699\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/2,3,50,54\">",
"     2,3,50,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74579851\">",
"    <span class=\"h2\">",
"     MDI technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important teaching points to emphasize regarding use of MDI devices include shaking the MDI before each actuation to ensure consistency of dosing from one actuation to the next and priming the MDI (wasting four doses, depending on the specific MDI) before initial use and if the MDI has not been used in two weeks or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/55-59\">",
"     55-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following basic steps for using a metered dose inhaler (MDI) are also provided in the Patient information handout. (See",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"     \"Patient information: How to use your metered dose inhaler (adults) (The Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If this is the first use of an HFA-MDI, the MDI will need to be primed: shake the MDI for 5 seconds and release four puffs into the air, away from the patient&rsquo;s face. Prior to each inhalation of medication, shake the inhaler for 5 seconds.",
"     </li>",
"     <li>",
"      Hold the inhaler upright with your finger on the top of the canister and your thumb on the bottom of the inhaler (",
"      <a class=\"graphic graphic_figure graphicRef55242 \" href=\"UTD.htm?24/52/25417\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Breathe out a normal breath.",
"     </li>",
"     <li>",
"      Close your lips around the mouthpiece, or hold the mouthpiece 1 to 2 inches (2 to 5 cm) in front of your mouth. Both the closed mouth and open mouth techniques are acceptable (",
"      <a class=\"graphic graphic_figure graphicRef55242 \" href=\"UTD.htm?24/52/25417\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      As you start to inhale the next breath, press down on the canister to actuate.",
"     </li>",
"     <li>",
"      Keep inhaling deeply and slowly through your mouth.",
"     </li>",
"     <li>",
"      When your lungs are full, hold your breath for 5 to 10 seconds to keep the medicine in your lungs.",
"     </li>",
"     <li>",
"      Let your breath out.",
"     </li>",
"     <li>",
"      If you are supposed to take 2 or more puffs of your inhaler, wait 15 to 30 seconds between puffs. Shake the inhaler again before each successive puff and repeat the steps above (you do not need to repeat the priming step).",
"     </li>",
"     <li>",
"      If you use a &ldquo;glucocorticoid&rdquo; (steroid) inhaler, rinse your mouth out with water, gargle, and spit out the water.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Correct technique with breath-activated MDIs may be taught in the same manner using the package insert for each device. In general, the key point is that the patient will need to take a deep and forceful inhalation to activate this type of MDI and continue inhaling after actuation until the lungs feel full. Patients who previously used chlorofluorocarbon (CFC)-based devices should be forewarned that non-CFC devices may have a different feel or taste than the CFC device; patients should also be reassured that this different feel does not mean the medicine is not reaching their lungs. (See",
"    <a class=\"local\" href=\"#H74579844\">",
"     'Types of inhaler devices'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    HFA inhalers must be cleaned on a regular basis to prevent medication build up and blockages. Most manufacturers recommend cleaning the mouthpiece at least once per week. To clean the MDI:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Remove the medication canister and cap from the mouthpiece. Do not wash the canister or immerse it in water.",
"     </li>",
"     <li>",
"      Clean the top and bottom of the plastic mouthpiece by running warm tap water through them for 30 to 60 seconds.",
"     </li>",
"     <li>",
"      Shake off excess water and allow the mouthpiece to dry completely (overnight is recommended).",
"     </li>",
"     <li>",
"      Replace the canister in the mouthpiece when dry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108641148\">",
"    <span class=\"h2\">",
"     MDI technique with spacer/chamber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spacers and valved holding chambers are accessory devices that reduce oropharyngeal deposition of MDI-delivered drug, improve distal delivery, and minimize the importance of hand-breath coordination. New",
"    <span class=\"nowrap\">",
"     spacer/chamber",
"    </span>",
"    devices may have a static charge on the inside surface and thus be less effective when it is new compared to after use or washing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Washing the device with dishwashing detergent prior to initial use and then allowing it to air-dry eliminates this static charge [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal technique for using an MDI with spacer or valved-holding chamber is as follows (",
"    <a class=\"graphic graphic_table graphicRef74044 \" href=\"UTD.htm?35/53/36699\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/37,65\">",
"     37,65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assemble",
"      <span class=\"nowrap\">",
"       spacer/chamber",
"      </span>",
"      and attach MDI.",
"     </li>",
"     <li>",
"      Shake canister vigorously for five seconds, then hold assembled",
"      <span class=\"nowrap\">",
"       canister-spacer/chamber",
"      </span>",
"      in a vertical position.",
"     </li>",
"     <li>",
"      Breathe out normally.",
"     </li>",
"     <li>",
"      Place mouthpiece of",
"      <span class=\"nowrap\">",
"       spacer/chamber",
"      </span>",
"      into mouth and close lips around mouthpiece.",
"     </li>",
"     <li>",
"      At the start of the next inhalation, actuate the MDI. When using a valved holding chamber, it is also acceptable to sequentially actuate the MDI into the chamber and then inhale.",
"     </li>",
"     <li>",
"      Keep inhaling deeply and slowly through your mouth. If you hear a whistling sound from the chamber, slow down the rate of inhalation.",
"     </li>",
"     <li>",
"      Hold your breath for 5 to 10 seconds.",
"     </li>",
"     <li>",
"      If your dose is two or more actuations, wait 15 to 30 seconds between actuations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discharging multiple doses into the chamber prior to a single inhalation will markedly reduce the amount of respirable drug available compared with individual actuation-inhalation cycles, so this practice should be discouraged [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/40,66,67\">",
"     40,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the powder residue that is deposited on the wall of the chamber is not harmful, the",
"    <span class=\"nowrap\">",
"     spacer/chamber",
"    </span>",
"    should be cleaned periodically, approximately every one to two weeks when the",
"    <span class=\"nowrap\">",
"     spacer/chamber",
"    </span>",
"    is used daily. Wash the",
"    <span class=\"nowrap\">",
"     spacer/chamber",
"    </span>",
"    with warm water and dilute dishwashing detergent. Washing with water alone causes an electrostatic charge to develop, reducing the effectiveness of the spacer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. After washing, air-dry the",
"    <span class=\"nowrap\">",
"     spacer/chamber",
"    </span>",
"    before the next use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3503338\">",
"    <span class=\"h2\">",
"     DPI technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic steps for using a dry powder inhaler (DPI) are provided in the table and also in the Patient information handout (",
"    <a class=\"graphic graphic_table graphicRef51020 \" href=\"UTD.htm?22/61/23516\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59737 \" href=\"UTD.htm?10/11/10429\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/37,65\">",
"     37,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"     \"Patient information: How to use your metered dose inhaler (adults) (The Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DPIs come in two main types (",
"    <a class=\"graphic graphic_picture graphicRef57922 \" href=\"UTD.htm?41/43/42675\">",
"     picture 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple dose devices, which contain up to 200 doses (eg, Advair Diskus",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Asmanex Twisthaler",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Pulmicort Flexhaler",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Serevent Diskus",
"      <sup>",
"       &reg;",
"      </sup>",
"      ). Among the multiple dose devices, the method for moving the medication containing powder into the holding chamber is either depressing a lever or twisting a part of the canister.",
"     </li>",
"     <li>",
"      Single dose devices (Foradil",
"      <sup>",
"       &reg;",
"      </sup>",
"      Aerolizer, Spiriva",
"      <sup>",
"       &reg;",
"      </sup>",
"      Handihaler), which require placement of a capsule in the device immediately before each treatment. DPI capsules should NOT be swallowed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients will need instructions for and demonstration of the correct use of the specific device they are prescribed (",
"    <a class=\"graphic graphic_table graphicRef51020 \" href=\"UTD.htm?22/61/23516\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59737 \" href=\"UTD.htm?10/11/10429\">",
"     table 4",
"    </a>",
"    ). The key points to emphasize are storing the DPI device at room temperature in a dry place, inhaling the medication forcefully and deeply, and not exhaling into the canister [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/34,35,68\">",
"     34,35,68",
"    </a>",
"    ]. The humid exhaled air can cause the powder to clump, impairing aerosolization, and reducing drug delivery to the airways.",
"   </p>",
"   <p>",
"    DPIs should not be washed with soap and water, as this can cause the medication to clump. The mouthpiece can be cleaned with a dry cloth, as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Determining when an inhaler device is empty",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important for the patient to be able to determine when an MDI canister is empty. A few MDIs (eg, Ventolin-HFA",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) are manufactured with integrated dose counters [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/69\">",
"     69",
"    </a>",
"    ]. As an alternative, electronic dose counters such as the 3M Integrated Dose by Dose Counter or the PuffMinder",
"    <sup>",
"     &reg;",
"    </sup>",
"    may be purchased and affixed to the MDI to track the number of doses used, which can then be subtracted from the total doses available. A lower-cost alternative would be for the patient to maintain a log of the number of actuations and dispose of the device when the designated number of actuations has been reached or estimate when the inhaler will become empty based on the number of puffs in the inhaler and the number of puffs typically used per day or week.",
"   </p>",
"   <p>",
"    The technique of dropping the MDI canister into a pan of water and observing how it floats has been shown to be unreliable and is no longer recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18856/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"     \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dry powder (DPI) devices have counters that display the number of puffs remaining or use individual capsules that can be counted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MECHANICALLY VENTILATED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of inhaled medications to mechanically ventilated patients requires special attention because of the propensity for deposition of the medication on ventilator tubing and the endotracheal tube. The methods for delivering inhaled medications to mechanically ventilated patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link&amp;anchor=H19#H19\">",
"     \"Delivery of inhaled medication in adults\", section on 'Mechanically ventilated patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=see_link\">",
"       \"Patient information: How to use your dry powder inhaler (adults) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"       \"Patient information: How to use your metered dose inhaler (adults) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74579735\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhaler devices are used to deliver a variety of inhaled medications, such as beta-agonists, anticholinergics, and glucocorticoids (",
"      <a class=\"graphic graphic_picture graphicRef62613 \" href=\"UTD.htm?37/43/38591\">",
"       picture 1",
"      </a>",
"      ). Two main types of inhaler devices are available, the pressurized metered dose inhaler (MDI) and the dry powder inhaler (DPI). (See",
"      <a class=\"local\" href=\"#H74579844\">",
"       'Types of inhaler devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The traditional MDI propellant, a chlorofluorocarbon (CFC), has largely been replaced with hydrofluoroalkane (HFA) due to environmental concerns. Despite a different taste and feel, the HFA propellant delivers medication to the lungs in an amount comparable to the CFC propellant. (See",
"      <a class=\"local\" href=\"#H74579844\">",
"       'Types of inhaler devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common problems with inhaler usage are deposition of medication in the oropharynx, poor coordination of actuation and inhalation, and insufficient breath-hold after inhalation. Correct technique for using inhaler devices delivers the medication to the airways of the lung with minimal oropharyngeal deposition, leading to better airway responses. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Common problems with inhaler devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have difficulty with proper MDI technique and for those who are using glucocorticoid-containing MDIs, use of a spacer device or valved holding chamber reduces oropharyngeal deposition and improves coordination of actuation and inhalation. Auto-actuating MDIs and DPI inhalers are additional methods to address actuation-inhalation problems. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Actuation-inhalation coordination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled medications can be delivered to patients receiving mechanical ventilation by using a pressurized MDI and actuating the device into a specialized chamber that is inserted in-line in the ventilator tubing (",
"      <a class=\"graphic graphic_picture graphicRef53295 \" href=\"UTD.htm?5/12/5327\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mechanically ventilated patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The basic steps for using a metered dose inhaler (MDI) are provided in the Patient information handout. (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"       \"Patient information: How to use your metered dose inhaler (adults) (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The basic steps for using a dry powder inhaler (DPI) are provided in the table and also in the Patient information handout (",
"      <a class=\"graphic graphic_table graphicRef51020 \" href=\"UTD.htm?22/61/23516\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef59737 \" href=\"UTD.htm?10/11/10429\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"       \"Patient information: How to use your metered dose inhaler (adults) (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/1\">",
"      Schecker MH, Wilson AF, Mukai DS, et al. A device for overcoming discoordination with metered-dose inhalers. J Allergy Clin Immunol 1993; 92:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/2\">",
"      Goodman DE, Israel E, Rosenberg M, et al. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med 1994; 150:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/3\">",
"      Toogood, JH. Helping your patients make better use of MDIs and spacers. J Respir Dis 1994; 15:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/4\">",
"      Sander N, Fusco-Walkert SJ, Harder JM, Chipps BE. Dose counting and the use of pressurized metered-dose inhalers: running on empty. Ann Allergy Asthma Immunol 2006; 97:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/5\">",
"      Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008; 75:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/6\">",
"      Souza ML, Meneghini AC, Ferraz E, et al. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J Bras Pneumol 2009; 35:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/7\">",
"      Sleath B, Ayala GX, Gillette C, et al. Provider demonstration and assessment of child device technique during pediatric asthma visits. Pediatrics 2011; 127:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/8\">",
"      Minai BA, Martin JE, Cohn RC. Results of a physician and respiratory therapist collaborative effort to improve long-term metered-dose inhaler technique in a pediatric asthma clinic. Respir Care 2004; 49:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/9\">",
"      Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. Int J Clin Pract 2009; 63:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/10\">",
"      Hawksworth RJ, Sykes AP, Faris M, et al. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2002; 88:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/11\">",
"      Langley SJ, Sykes AP, Batty EP, et al. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Ann Allergy Asthma Immunol 2002; 88:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/12\">",
"      Cheng YS, Fu CS, Yazzie D, Zhou Y. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med 2001; 14:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/13\">",
"      Richards J, Hirst P, Pitcairn G, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001; 14:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/14\">",
"      Boccuzzi SJ, Wogen J, Roehm JB. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. Clin Ther 2000; 22:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/15\">",
"      Huchon G, Hofbauer P, Cannizzaro G, et al. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur Respir J 2000; 15:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/16\">",
"      Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir Med 2000; 94:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/17\">",
"      Shapiro G, Bronsky E, Murray A, et al. Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma. Arch Pediatr Adolesc Med 2000; 154:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/18\">",
"      Brindley A. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability. J Allergy Clin Immunol 1999; 104:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/19\">",
"      Bronsky E, Ekholm BP, Klinger NM, Colice GL. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. J Asthma 1999; 36:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/20\">",
"      Ramsdell JW, Klinger NM, Ekholm BP, Colice GL. Safety of long-term treatment with HFA albuterol. Chest 1999; 115:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/21\">",
"      Bleecker ER, Tinkelman DG, Ramsdell J, et al. Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. Chest 1998; 113:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/22\">",
"      Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care 2005; 50:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/23\">",
"      Escribano A, Tutuncu A, L&ouml;hr I, et al. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial. Curr Med Res Opin 2006; 22:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/24\">",
"      Singh D, Tutuncu A, Lohr I, et al. Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence. Int J Clin Pharmacol Ther 2007; 45:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/25\">",
"      Shapiro GS, Klinger NM, Ekholm BP, Colice GL. Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma. J Asthma 2000; 37:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/26\">",
"      Pickering H, Pitcairn GR, Hirst PH, et al. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. Clin Ther 2000; 22:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/27\">",
"      Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/28\">",
"      Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005; 61:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/29\">",
"      Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999; 104:S250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/30\">",
"      Leach CL, Colice GL. A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times. J Aerosol Med Pulm Drug Deliv 2010; 23:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/31\">",
"      Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers. Chest 2002; 122:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/32\">",
"      Dhand R. Aerosol therapy for asthma. Curr Opin Pulm Med 2000; 6:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/33\">",
"      Nana A, Youngchaiyud P, Maranetra N, et al. Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med 1998; 92:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/34\">",
"      Broeders ME, Molema J, Vermue NA, Folgering HT. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J 2001; 18:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/35\">",
"      Chavan V, Dalby R. Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers. AAPS PharmSci 2000; 2:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/36\">",
"      Kanabuchi K, Kondo T, Tanigaki T, et al. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship. Tokai J Exp Clin Med 2011; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/37\">",
"      Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000; 45:874.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/39\">",
"      Dempsey OJ, Wilson AM, Coutie WJ, Lipworth BJ. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest 1999; 116:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/40\">",
"      O'Callaghan C, Barry P. Spacer devices in the treatment of asthma. BMJ 1997; 314:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/41\">",
"      Barry PW, O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax 1996; 51:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/42\">",
"      Bisgaard H, Anh&oslash;j J, Klug B, Berg E. A non-electrostatic spacer for aerosol delivery. Arch Dis Child 1995; 73:226.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Program, NIH publication no. 97-4051 USDHHS, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/44\">",
"      Dickens GR, Wermeling DP, Matheny CJ, et al. Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. Ann Allergy Asthma Immunol 2000; 84:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/45\">",
"      Hampson NB, Mueller MP. Reduction in patient timing errors using a breath-activated metered dose inhaler. Chest 1994; 106:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/46\">",
"      Kamin WE, Genz T, Roeder S, et al. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J Aerosol Med 2002; 15:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/47\">",
"      Marshik PL, Larsen JS, Leach CL, et al. A novel breath actuated device (Autohaler) consistently actuates during the early phase of inspiration. J Aerosol Med 1995; 8:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/48\">",
"      Niggemann B. Breath-actuated metered-dose inhaler. J Allergy Clin Immunol 1995; 95:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/49\">",
"      Chapman KR, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects. Chest 1993; 104:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/50\">",
"      Manzella BA, Brooks CM, Richards JM Jr, et al. Assessing the use of metered dose inhalers by adults with asthma. J Asthma 1989; 26:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/51\">",
"      Bailey WC, Richards JM Jr, Brooks CM, et al. A randomized trial to improve self-management practices of adults with asthma. Arch Intern Med 1990; 150:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/52\">",
"      Ram FS, Wright J, Brocklebank D, White JE. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma. BMJ 2001; 323:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/53\">",
"      Gross G, Cohen RM, Guy H. Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. J Asthma 2003; 40:487.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education Program. Teach your patients about asthma. A clinician's guide. National Institutes of Health, Bethesda, 1992, Pub. #92-2737.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/55\">",
"      Blake KV, Harman E, Hendeles L. Evaluation of a generic albuterol metered-dose inhaler: importance of priming the MDI. Ann Allergy 1992; 68:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/56\">",
"      Ross RN. Loss of bronchodilator medication in priming a conventional metered dose inhaler: a cost of treating asthma. Med Interface 1997; 10:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/57\">",
"      Cyr TD, Graham SJ, Li KY, Lovering EG. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 1991; 8:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/58\">",
"      Everard ML, Devadason SG, Summers QA, Le Sou&euml;f PN. Factors affecting total and \"respirable\" dose delivered by a salbutamol metered dose inhaler. Thorax 1995; 50:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/59\">",
"      Berg E. In vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med 1995; 8 Suppl 3:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/60\">",
"      Dompeling E, Oudesluys-Murphy AM, Janssens HM, et al. Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge. Arch Dis Child 2001; 84:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/61\">",
"      Anh&oslash;j J, Bisgaard H, Lipworth BJ. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. Br J Clin Pharmacol 1999; 47:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/62\">",
"      van der Veen MJ, van der Zee JS. Aerosol recovery from large-volume reservoir delivery systems is highly dependent on the static properties of the reservoir. Eur Respir J 1999; 13:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/63\">",
"      Wildhaber JH, Janssens HM, Pi&eacute;rart F, et al. High-percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000; 29:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/64\">",
"      Pi&eacute;rart F, Wildhaber JH, Vrancken I, et al. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J 1999; 13:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/65\">",
"      Kacmarek, DM, Hess, D. The interface between patient and aerosol generator. Respir Care 1991; 36:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/66\">",
"      Rau JL, Restrepo RD, Deshpande V. Inhalation of single vs multiple metered-dose bronchodilator actuations from reservoir devices. An in vitro study. Chest 1996; 109:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/67\">",
"      Barry PW, O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 1995; 40:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/68\">",
"      Smith KJ, Chan HK, Brown KF. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J Aerosol Med 1998; 11:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/69\">",
"      Rickard KA. Not running on empty. Ann Allergy Asthma Immunol 2006; 97:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/70\">",
"      Cain WT, Oppenheimer JJ. The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices. Ann Allergy Asthma Immunol 2001; 87:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18856/abstract/71\">",
"      Ogren RA, Baldwin JL, Simon RA. How patients determine when to replace their metered-dose inhalers. Ann Allergy Asthma Immunol 1995; 75:485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 559 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18856=[""].join("\n");
var outline_f18_26_18856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H74579735\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74579844\">",
"      TYPES OF INHALER DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85082029\">",
"      Metered dose inhalers with CFC and HFA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85082036\">",
"      Dry powder inhalers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62570469\">",
"      SPACERS AND HOLDING CHAMBERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMMON PROBLEMS WITH INHALER DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Upper airway deposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Actuation-inhalation coordination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62571105\">",
"      Insufficient breath-hold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TEACHING INHALER USE SKILLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74579851\">",
"      MDI technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108641148\">",
"      MDI technique with spacer/chamber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3503338\">",
"      DPI technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Determining when an inhaler device is empty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MECHANICALLY VENTILATED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74579735\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/559\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/559|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/52/25417\" title=\"figure 1\">",
"      Inhaler instructions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/559|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/43/38591\" title=\"picture 1\">",
"      Metered dose inhaler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/4/22607\" title=\"picture 2\">",
"      MDI spacers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/43/42675\" title=\"picture 3\">",
"      Dry powder inhalers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/12/5327\" title=\"picture 4\">",
"      MDI in-line spacer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/559|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/10/17581\" title=\"table 1\">",
"      Aerosol device comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/53/36699\" title=\"table 2\">",
"      Using MDI PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/61/23516\" title=\"table 3\">",
"      Using powder inhalers 1 PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/11/10429\" title=\"table 4\">",
"      Using powder inhalers 2 PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/47/9970?source=related_link\">",
"      Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=related_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_26_18857="Motor fluctuations and dyskinesia in Parkinson disease";
var content_f18_26_18857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Motor fluctuations and dyskinesia in Parkinson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/26/18857/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18857/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/26/18857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18857/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/26/18857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/26/18857/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/26/18857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 50 percent of patients on levodopa for five years experience motor fluctuations (MF) and dyskinesia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/1\">",
"     1",
"    </a>",
"    ]. These symptoms are especially common in patients with young-onset (eg, under the age of 50) Parkinson disease (PD); they are unique to levodopa and are not produced by the other antiparkinson drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients typically experience a smooth and even response to the early stages of levodopa treatment. As the disease advances, however, the effect of levodopa begins to wear off approximately four hours after each dose, leaving patients anticipating the need for their next dose. This phenomenon may be explained by the observation that dopamine nerve terminals are able to store and release dopamine early in the course of disease but, with more advanced disease and increasing degeneration of dopamine terminals, the concentration of dopamine in the basal ganglia is much more dependent upon plasma levodopa levels. Plasma levels may fluctuate erratically because of the 90 minute half-life of levodopa and the frequently unpredictable intestinal absorption of this medication.",
"   </p>",
"   <p>",
"    Motor fluctuations (MF) are alterations between periods of being \"on,\" during which the patient enjoys a good response to medication, and being \"off\" during which the patient experiences symptoms of their underlying parkinsonism.",
"   </p>",
"   <p>",
"    Dyskinesia consists of abnormal involuntary movements that are usually choreic or dystonic but, when more severe, may be ballistic or myoclonic. Dyskinesia usually appears when the patient is \"on.\" It may occasionally occur in the form of painful dystonia when the patient is \"off,\" especially in the morning on awakening, when dystonic intorsion of a foot (usually on the side of greater parkinsonian involvement) occurs as a withdrawal reaction because of the long interval without medication overnight.",
"   </p>",
"   <p>",
"    This topic review will discuss the medical management of patients with more advanced PD who are experiencing MF. The general approach to therapy of PD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery for advanced PD is another therapeutic option, as bilateral deep brain stimulation of the subthalamic nucleus or globus pallidus appears to improve motor function in selected patients with advanced typical PD and MF, whose condition cannot be further improved by medical therapy. The surgical management of advanced PD is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link\">",
"     \"Surgical treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WEARING-OFF PHENOMENON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced Parkinson disease (PD) begin to be aware of a wearing \"off\" or end-of-dose effect less than four hours following a dose of levodopa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Alteration of levodopa dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wearing \"off\" can be managed initially by increasing the dose of levodopa, if the patient is not having side effects and is taking a relatively low dose. However, increasing the dose often increases side effects without effectively increasing the dose duration.",
"   </p>",
"   <p>",
"    Shortening the interdose interval while administering lower doses is usually a more effective approach. However, it is often difficult to titrate the dose precisely, and some patients begin to exhibit an \"all or none\" response whereby individual lower doses produce no evident clinical response. This occurs because the pharmacologic response threshold is higher in advanced disease than it is in earlier disease.",
"   </p>",
"   <p>",
"    Liquid Sinemet (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    ) is occasionally used for patients when titration of the dose and dose interval using tablets is difficult. However, this approach is not typically practical since Sinemet is insoluble in water and no commercial preparation of liquid Sinemet is available. Instructions for preparation of a daily supply of liquid Sinemet are available, but use of this approach is best left to the specialist [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sustained-release forms of levodopa preparations (eg, Sinemet CR) may be useful in the early stages of the wearing \"off\" phenomenon and may add up to 90 additional minutes throughout the day to levodopa's duration of effect [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/3\">",
"     3",
"    </a>",
"    ]. However, Sinemet CR is less well absorbed than immediate release Sinemet; thus, an individual dose increase of approximately 30 percent may be required to achieve the same clinical response.",
"   </p>",
"   <p>",
"    After a review of the available studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/3-6\">",
"     3-6",
"    </a>",
"    ], a practice parameter from the American Academy of Neurology (AAN) issued in 2006 concluded that sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    does not decrease \"off\" time compared with immediate release formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Addition of a second drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;Addition of a second drug is indicated if the adjustments cited above are not successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dopamine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine agonists are commonly used to reduce the amount of \"off\" time in patients with advanced PD and may also allow for the dose of levodopa to be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/8-14\">",
"     8-14",
"    </a>",
"    ]. The dopamine agonists include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/45/5846?source=see_link\">",
"     rotigotine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Pergolide was withdrawn from the United States market in 2007 due to the potential risk of heart valve damage.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     Cabergoline",
"    </a>",
"    , a long-acting dopamine agonist, has also been associated with heart valve damage. Cabergoline was approved in the United States only for the treatment of hyperprolactinemic disorders but",
"    <strong>",
"     not",
"    </strong>",
"    for treatment of PD, and is still considered safe because of the low doses used for its approved indication.",
"   </p>",
"   <p>",
"    Studies comparing the efficacy of various dopamine agonists have found either no significant difference or only mild superiority of one agent over another [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/15-20\">",
"     15-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dopamine agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    administered subcutaneously can be used for rapid onset (usually within 10 minutes) rescue therapy when patients suddenly turn \"off\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/21\">",
"     21",
"    </a>",
"    ]. In a randomized, double-blind, placebo-controlled study of 29 patients with advanced PD and two hours or more of \"off\" time despite aggressive oral therapy, administration of subcutaneous apomorphine (2 to 10 mg) resulted in successful amelioration of \"off\" state events following 95 percent of injections compared with 23 percent receiving placebo injection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One review concluded that the magnitude and pattern of the motor response to a single subcutaneous dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    is qualitatively comparable to that of oral levodopa; a 4 mg dose achieved a clinically significant improvement in 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     Cabergoline",
"    </a>",
"    may have some utility for reduction of \"off\" time in patients with advanced PD, but data are limited. In a single center, 24-week study of 37 patients (19 active, 18 placebo), treatment with cabergoline (mean dose 5.4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was associated with a significant decrease in daily \"off\" time compared with placebo (2 versus 0.7 hours [40 versus 18 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/24\">",
"     24",
"    </a>",
"    ]. However, these results are limited by a potentially confounding baseline difference in \"off\" time duration between the treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/7\">",
"     7",
"    </a>",
"    ]. In another single center, 24-week study of 27 patients (17 active, 10 placebo), patients treated with cabergoline (mean dose 4.9",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    had an increase in \"on\" time (2.7 hours [30 percent]) and a decrease in \"off\" time (3.3 hours [59 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/25\">",
"     25",
"    </a>",
"    ], but no information was provided for the placebo group about these parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     Cabergoline",
"    </a>",
"    treatment was not associated with increased dyskinesia in these trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, a retrospective case control study of 210 patients with PD found that high cumulative dose and long-term treatment with cabergoline was associated with an increased risk of cardiac valvulopathy detected on transthoracic echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized controlled trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    decreased \"off\" time compared with placebo (8 versus 3 percent, respectively), but the difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     COMT inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catechol-O-methyl transferase (COMT) inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    (Tasmar) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"     entacapone",
"    </a>",
"    (Comtan) may prolong and potentiate the levodopa effect and reduce the \"off\" time when given with a dose of levodopa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. The net result is an increased levodopa effect in fluctuating patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/27,32\">",
"     27,32",
"    </a>",
"    ]. These medications may allow a reduction in the total daily levodopa dose by as much as 30 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link&amp;anchor=H22#H22\">",
"     \"Pharmacologic treatment of Parkinson disease\", section on 'COMT inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    is 100 mg three times daily; the clinical effect is evident immediately.",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"     entacapone",
"    </a>",
"    is one 200 mg tablet with each dose of levodopa, up to a maximum of eight doses per day.",
"   </p>",
"   <p>",
"    The most common side effects of these drugs are due to increased dopaminergic stimulation and include dyskinesia, psychiatric effects (mainly visual hallucinations), nausea, diarrhea, and orthostatic hypotension. The adverse effects are managed by lowering the dose of levodopa either before or after the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"     entacapone",
"    </a>",
"    . Both drugs may also cause a brown-orange urine discoloration.",
"   </p>",
"   <p>",
"    In clinical trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    was associated with transient, asymptomatic elevations of transaminases (AST and ALT) in 1 to 3 percent of subjects exposed to the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/33\">",
"     33",
"    </a>",
"    ]. Three reported deaths from hepatotoxicity in patients using tolcapone prompted its removal from the market in Canada and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/33\">",
"     33",
"    </a>",
"    ], although it is still available in the United States with the recommendation that it be used for treatment of motor fluctuations only after other methods have been exhausted and with monitoring of ALT and AST levels for the first six months of therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"     Entacapone",
"    </a>",
"    has thus far not been associated with hepatotoxicity.",
"   </p>",
"   <p>",
"    Monitoring of liver enzymes with liver function tests (LFTs) must be done at baseline and then every two weeks for the first year of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    therapy, then every four weeks for the next six months, then every eight weeks thereafter. Monitoring of LFTs should be resumed at the previous frequency if the tolcapone dose is increased to 200 mg three times a day. Tolcapone should be discontinued if the ALT or AST exceeds the upper limit of normal or if the clinical signs and symptoms suggest the onset of liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     MAO B inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     Rasagiline",
"    </a>",
"    is a selective monoamine oxidase (MAO) B inhibitor. It has potential long-term effects on dopamine transmission because it acts irreversibly on MAO B receptors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     Rasagiline",
"    </a>",
"    appears to be effective for motor complications in PD as demonstrated in randomized clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. One of these, the 18-week multicenter LARGO trial, evaluated 687 patients with PD who had motor fluctuations (MF) for at least one hour every day despite optimum",
"    <span class=\"nowrap\">",
"     levodopa/dopa",
"    </span>",
"    decarboxylase therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients were randomly assigned to adjunct therapy with either rasagiline 1 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"     entacapone",
"    </a>",
"    200 mg with every levodopa dose, or placebo. Both rasagiline and entacapone reduced mean daily \"off\" time (the primary outcome measure) by about one hour compared with placebo, and both increased daily \"on\" time without troublesome dyskinesia compared with placebo. The beneficial effect of rasagiline was independent of age (&lt;70 versus &ge;70 years) and of adjunct use of dopamine agonists.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     Rasagiline",
"    </a>",
"    was well tolerated in these studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. The frequency of dopaminergic adverse events in the LARGO trial was similar to that seen in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"     entacapone",
"    </a>",
"    and placebo groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     Selegiline",
"    </a>",
"    is another selective MAO B inhibitor. Unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     rasagiline",
"    </a>",
"    , selegiline is metabolized to amphetamine derivatives. Although selegiline may extend the levodopa effect, the clinical benefit this produces is usually relatively mild [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/35\">",
"     35",
"    </a>",
"    ]. Results from a small randomized controlled trial suggest that orally disintegrating selegiline may also be beneficial, although the study did not report change in levodopa dose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergic drugs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    are not very effective in managing the wearing \"off\" effect and are rarely indicated for this purpose, given the other more effective options.",
"   </p>",
"   <p>",
"    Preliminary studies suggest that eradication of Helicobacter colonization, which is present in about half of the population, may be a useful method for improving levodopa absorption and reducing motor fluctuations in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Confirmation in larger clinical trials is needed before routine testing for H. pylori and antibiotic eradication can be recommended.",
"   </p>",
"   <p>",
"    Adjunctive therapy with istradefylline, an adenosine A2A receptor antagonist, appeared promising in early studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], but a larger trial found that the benefit in reduced \"off\" time was modest [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/41\">",
"     41",
"    </a>",
"    ]. Further development of the drug has been halted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Guideline recommendations for treating \"off\" time",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evidenced-based practice parameter from the AAN issued in 2006 made the following recommendations for the treatment of \"off\" time in patients with PD and motor fluctuations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"       Entacapone",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H6\">",
"       'COMT inhibitors'",
"      </a>",
"      above) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"       rasagiline",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H7\">",
"       'MAO B inhibitors'",
"      </a>",
"      above) are established as effective and should be offered to reduce \"off\" time",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"       Pramipexole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"       ropinirole",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Dopamine agonists'",
"      </a>",
"      above), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/47/33526?source=see_link\">",
"       tolcapone",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H6\">",
"       'COMT inhibitors'",
"      </a>",
"      above) are probably effective and should be considered to reduce \"off\" time, with the stipulation that the adverse effects of tolcapone (hepatotoxicity) requires that it be used with caution and monitoring",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"       Apomorphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Dopamine agonists'",
"      </a>",
"      above), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"       selegiline",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H7\">",
"       'MAO B inhibitors'",
"      </a>",
"      above) are possibly effective and may be considered to reduce \"off\" time",
"     </li>",
"     <li>",
"      Sustained release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"       carbidopa-levodopa",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Alteration of levodopa dosing'",
"      </a>",
"      above) does not decrease \"off\" time compared with immediate release carbidopa-levodopa;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Dopamine agonists'",
"      </a>",
"      above) does not reduce \"off\" time compared with placebo; both may be disregarded to reduce \"off\" time",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     UNPREDICTABLE OFF PERIODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transitions from being \"on\" to being \"off\" can be sudden and unpredictable in some patients. Unlike the wearing \"off\" phenomenon at the end of a levodopa dose cycle, there is sometimes no obvious relationship between the time of levodopa administration and the appearance of \"off\" episodes in patients with unpredictable \"off\" periods. These periods typically occur in patients with advanced Parkinson disease (PD) who are also experiencing motor fluctuations (MF) and severe dyskinesia (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Dyskinesia'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Management of these individuals is similar to that for patients who are having problems with wearing \"off,\" although it typically is much more difficult. Direct observation of the patient during a prolonged outpatient visit as he or she cycles through such episodes is useful to determine the relationship of levodopa doses to \"off\" episodes. In some cases, these episodes occur at times of peak levodopa effect due to excessive rather than insufficient dopaminergic stimulation; such patients are best treated by reducing rather than raising the levodopa dose.",
"   </p>",
"   <p>",
"    Addition of a COMT inhibitor or a dopamine agonist can be helpful; marked reduction of the levodopa dose together with the addition of high doses of a dopamine agonist may be required. Controlled release levodopa preparations (eg, Sinemet CR) are usually",
"    <strong>",
"     not",
"    </strong>",
"    helpful and occasionally exacerbate the situation.",
"   </p>",
"   <p>",
"    Competition with neutral amino acids for transport across the gut and into the brain may be responsible for \"offs\" that appear following meals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/42\">",
"     42",
"    </a>",
"    ]. A protein redistribution diet in which most protein intake is reserved for the evening was useful in approximately two-thirds of such patients in small studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], although this type of diet tends to be impractical for long-term use.",
"   </p>",
"   <p>",
"    Freezing of gait (FOG) can occur as a transient &ldquo;off&rdquo; phenomenon, treatable by the above strategies, or randomly at variable frequency in patients with advanced PD. Random freezing is notoriously unresponsive to any of the currently available treatment modalities, including antiparkinson medications and deep brain stimulation. During an episode of FOG, patients suddenly become immobilized for seconds to minutes at a time, usually when in a confined space such as a doorway or a closet, or when getting on or off an elevator. An episode of FOG can lead to falling, usually forward. There are conflicting data from two small randomized controlled trials regarding the utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    for gait freezing and hypokinesia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. When freezing is more prolonged and accompanied by the emergence of other parkinsonian signs, treatment is similar to patients with other forms of the wearing \"off\" effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ACUTE AKINESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute akinesia is a sudden exacerbation of Parkinson disease (PD) characterized by an akinetic state that lasts for several days and does not respond to treatment with antiparkinson medication. This phenomenon is different from wearing \"off\" effects (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Wearing-off phenomenon'",
"    </a>",
"    above) and may occur in patients not previously treated with levodopa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute akinesia should prompt a search for systemic infection or other intercurrent medical problems that are capable of causing a sudden worsening of parkinsonism. In a review of this problem in 26 patients, acute akinesia appeared after a flu-like syndrome in six patients, hip joint surgery or bone fractures in eight patients, gastrointestinal disturbances in three patients, and various medication manipulations in the remaining patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/47\">",
"     47",
"    </a>",
"    ]. Four patients died in spite of treatment.",
"   </p>",
"   <p>",
"    Episodes of acute akinesia may therefore have serious consequences and usually warrant acute hospitalization in order to identify and correct the underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FAILURE OF ON-RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with motor fluctuations (MF) sometimes fail to turn \"on\" following a dose of levodopa. This has been called the \"no-on\" response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/48\">",
"     48",
"    </a>",
"    ]. In some cases, this is due to delayed gastric motility, which results in inadequate plasma concentrations in advanced patients who have a narrow therapeutic window. A common reason for the \"no-on\" phenomenon is an excessively prolonged or severe \"off\" period occurring before the \"no-on.\" This is best managed by avoiding \"offs.\" (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Wearing-off phenomenon'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The prokinetic agent cisapride increases gastrointestinal motility and may be helpful in such patients, but the drug has been associated with a number of drug interactions and fatal cardiac arrhythmias, prompting the manufacturer to severely restrict its availability in the United States. The prokinetic drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    is a dopamine receptor blocker that should be avoided. Patients should be encouraged to take levodopa on an empty stomach and avoid protein at the time of drug administration.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     Domperidone",
"    </a>",
"    is a D2-blocker with selective peripheral activity in the upper gastrointestinal tract; it does not cross the blood-brain barrier and therefore lacks the neurologic side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    . It is currently not available in the United States but is available in Canada and other countries. Although data are limited, domperidone (starting at 20 mg four times daily) may be useful as a prokinetic agent to treat delayed gastric emptying in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, animal studies suggest that, like cisapride, domperidone may increase the risk of cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DYSKINESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyskinesia refers to a variety of involuntary movements, which occur as a direct effect of levodopa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/52\">",
"     52",
"    </a>",
"    ]. Other antiparkinson drugs are much less likely to produce these motor abnormalities but may exacerbate them once they have appeared following treatment with levodopa. Dyskinesia is sometimes mistaken for manifestations of progressive Parkinson disease (PD) or confused with tremor by patients and their families, rather than recognized as reversible consequences of treatment.",
"   </p>",
"   <p>",
"    Dyskinesia occurs in 30 to 40 percent of patients treated with levodopa by five years and nearly 60 percent by ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], but not all dyskinesia requires treatment. A retrospective study suggests that the rate of dyskinesia requiring medication adjustment at five and ten years after levodopa treatment is 17 and 43 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peak dose or &ldquo;on&rdquo; dyskinesia is usually choreiform in type. It is manifested by the appearance of restlessness and continuous jerky, involuntary movements of the extremities, head, face, trunk, and respiratory muscles, typically starting 30 to 60 minutes after a dose of levodopa. These dyskinetic movements are remarkably well tolerated by most patients since they feel entirely relieved of their parkinsonism while dyskinesia is present. However, severe dyskinesia may take the form of large amplitude, ballistic movements that interfere with function and become very disturbing to patients and their families. Dyskinesia can also take the form of dystonic posturing, which more commonly occurs during an &ldquo;off&rdquo; period.",
"   </p>",
"   <p>",
"    Levodopa was given in relatively high doses when it was first used as therapy for PD. As a result, dyskinesia was often seen early in treatment, especially in those with advanced disease who were being treated for the first time. The subsequent use of more modest doses resulted in its later appearance, months to years after initiating levodopa. Dyskinesia is especially common in patients with young-onset PD.",
"   </p>",
"   <p>",
"    Peak-dose dyskinesia is most common [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/52\">",
"     52",
"    </a>",
"    ]. It occurs 60 to 90 minutes following a dose of levodopa. Early in the disease, this complication can be managed by lowering the medication dose, switching to a controlled release preparation, or reducing adjunctive drugs such as dopamine agonists,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    , or anticholinergic drugs. However, in more advanced patients with brittle responses, reducing the dose of levodopa may result in complete failure to generate an \"on\" response. In this situation, the dose of dopamine agonist should be greatly increased and the levodopa dose reduced, since dopamine agonists are much less likely to induce dyskinesia than levodopa.",
"   </p>",
"   <p>",
"    An unusual pattern sometimes evolves in which dyskinesia peaks twice after each dose (diphasic dyskinesia) &ndash; when patients turn \"on\" and again as they begin to turn \"off\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/52\">",
"     52",
"    </a>",
"    ]. In the second phase, dyskinesia (usually dystonic posturing) in one body part may coexist with the emergence elsewhere of parkinsonian signs such as tremor and dyskinesia. This pattern is often unrecognized and may only be appreciated if the patient is observed during a prolonged outpatient visit.",
"   </p>",
"   <p>",
"    The diphasic pattern is notoriously difficult to manage and usually requires more frequent levodopa dosing to prevent wearing \"off\" and the re-emergence of &ldquo;off&rdquo; dystonia prior to each dose. However, this strategy often leads to progressively increasing peak-dose dyskinesia as the day goes on. Addition of a dopamine agonist and a marked reduction in the levodopa dose should be tried in such patients.",
"   </p>",
"   <p>",
"    Sustained release levodopa is best",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with severe or complex patterns of dyskinesia since absorption may be delayed and dyskinesia tends to progressively increase into the afternoon and evening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Amantadine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    may be useful for treating dyskinesia in advanced PD. Several studies have shown short-term benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. As an example, a single-center randomized controlled trial found that amantadine administration compared with placebo was associated with a 24 percent reduction in the total dyskinesia score [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/57\">",
"     57",
"    </a>",
"    ]. In addition, a placebo-controlled study involving 17 patients showed that the beneficial effects of amantadine on motor response fluctuations were maintained for at least one year; initial and one-year reductions in dyskinesia scores were 60 and 56 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another placebo-controlled study in 40 patients with dyskinesia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    treatment for 15 days resulted in a 45 percent reduction in dyskinesia scores compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/59\">",
"     59",
"    </a>",
"    ]. However, the benefit in this study lasted less than eight months, and amantadine withdrawal resulted in a rebound with increase of dyskinesia in 11 patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    was not associated with worsening of parkinsonism symptoms in these studies.",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    for dyskinesia is one tablet (100 mg) one to three times a day. Side effects may include peripheral edema, psychosis, and livedo reticularis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clozapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low doses of the antipsychotic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    (30 to 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    reduced dyskinesia in several open-label studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], and low dose clozapine (12.5 to 75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was significantly more effective than placebo in treating levodopa-induced dyskinesia in a double-blind, randomized controlled trial of 50 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/62\">",
"     62",
"    </a>",
"    ]. The usefulness of clozapine is limited by its potential for inducing bone marrow suppression, but this risk may be acceptably low with monitoring. Clozapine treatment requires obtaining the white blood cell count (WBC) and absolute neutrophil count (ANC) at baseline and weekly for the first six months of continuous treatment, followed by biweekly monitoring thereafter.",
"   </p>",
"   <p>",
"    The dibenzodiazepine derivative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    has similar properties to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    . In a randomized controlled trial of 10 patients with PD, low-dose olanzapine was effective in reducing dyskinesia, but was associated with unacceptable increases in parkinsonism and \"off\" time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Guideline recommendations for reducing dyskinesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evidenced-based practice parameter from the AAN issued in 2006 made the following recommendations for the treatment of dyskinesia in patients with PD and motor fluctuations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/26/18857/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       Amantadine",
"      </a>",
"      is possibly effective and may be considered for reducing dyskinesia (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Amantadine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      There is insufficient evidence to support or refute the effectiveness of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      in reducing dyskinesia (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Clozapine'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DYSTONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dystonia is a more sustained abnormal posture than dyskinesia. Dystonic postures usually involve the limbs but can affect the face, neck, or trunk.",
"   </p>",
"   <p>",
"    Dystonia can be a manifestation of early untreated Parkinson disease (PD) or may appear as a complication of levodopa treatment. A careful history is required since, when due to levodopa, dystonia can occur either as a peak levodopa effect or during \"off\" periods due to levodopa withdrawal. Withdrawal dystonia most commonly occurs in the early morning when it produces painful flexion and inversion postures of the feet and toes.",
"   </p>",
"   <p>",
"    Peak dystonia is managed similarly to peak dyskinesia. \"Off\" period dystonia that occurs early in the morning is managed either by taking sustained release levodopa before retiring or by taking levodopa or a dopamine agonist during the night or first thing in the morning before arising. \"Off\" period dystonia during the day is managed similarly to other forms of the wearing \"off\" effect.",
"   </p>",
"   <p>",
"    Another form of levodopa withdrawal is akathisia (motor restlessness) or restless legs, which usually occurs at night, several hours after the last dose of levodopa. This is managed by providing levodopa or a dopamine agonist before retiring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=see_link\">",
"       \"Patient information: Parkinson disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/8/34947?source=see_link\">",
"       \"Patient information: Medicines for Parkinson disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following treatment suggestions represent my approach to some difficult management issues that occur in advanced Parkinson disease (PD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Wearing \"off\" phenomenon",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Document the pattern of motor fluctuations (MF). Obtain a careful and accurate history, and observe the patient directly in an outpatient setting.",
"     </li>",
"     <li>",
"      Examine the effect of diet, and avoid taking levodopa with high protein meals.",
"     </li>",
"     <li>",
"      A sustained-release levodopa formulation may be beneficial, but only in the early stages of wearing \"off\" in patients with less advanced PD. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Alteration of levodopa dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with more advanced PD, reduce the levodopa dose interval by 30 to 60 minutes. This may require the addition of an extra levodopa dose at the end of the day. In most cases, individual levodopa doses should be left unchanged. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Alteration of levodopa dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consider adding the COMT inhibitors",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"       entacapone",
"      </a>",
"      (Comtan) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/47/33526?source=see_link\">",
"       tolcapone",
"      </a>",
"      (Tasmar). Entacapone should be given first because of the small risk that tolcapone can cause an elevation of liver enzymes. Be prepared to lower the levodopa dose by up to 30 percent because of the increased peak levodopa effect if tolcapone is used. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'COMT inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consider adding an oral dopamine agonist such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"       pramipexole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"       ropinirole",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H5\">",
"       'Dopamine agonists'",
"      </a>",
"      above). Watch for dopaminergic toxicity such as visual hallucinations and confusion, and be prepared to lower the levodopa dose.",
"     </li>",
"     <li>",
"      Consider parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"       apomorphine",
"      </a>",
"      in patients with sudden and severe wearing \"off\" effects. This rescue therapy is very effective, but it has the disadvantage of requiring a prophylactic antiemetic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/63/4085?source=see_link\">",
"       trimethobenzamide",
"      </a>",
"      . In addition, the effective dose of parenteral apomorphine must be established for each patient by administration during a prolonged outpatient evaluation prior to initiating therapy.",
"     </li>",
"     <li>",
"      Consider the MAO B inhibitors",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"       rasagiline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"       selegiline",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H7\">",
"       'MAO B inhibitors'",
"      </a>",
"      above). Be aware that selegiline exerts only a mild effect on the wearing \"off\" phenomenon, while rasagiline has an effect comparable to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"       entacapone",
"      </a>",
"      . Rasagiline is now approved in the United States and in the European Union.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Unpredictable \"off\" periods",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Document that \"off\" periods are unpredictable and long lasting. In many cases, they are sudden wearing \"off\" effects or transient freezing episodes",
"     </li>",
"     <li>",
"      Avoid taking levodopa with high protein meals",
"     </li>",
"     <li>",
"      Evaluate and treat the possible effects of anxiety, which may precipitate sudden \"off\" episodes",
"     </li>",
"     <li>",
"      Consider raising the levodopa dose. Plasma levodopa levels may be falling below the therapeutic threshold",
"     </li>",
"     <li>",
"      Alternatively, consider lowering the levodopa dose. In rare cases, sudden \"off\" episodes may be due to excessive levodopa effects",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Failure or delay of the \"on\" response",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid taking levodopa with high protein meals",
"     </li>",
"     <li>",
"      Examine gastrointestinal absorption",
"     </li>",
"     <li>",
"      Avoid wearing \"off\" effects. Failure or delay of the \"on\" responses often occur after prolonged wearing \"off\" episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dyskinesia and dystonia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower the levodopa dose when possible",
"     </li>",
"     <li>",
"      Replace a portion of the levodopa dose with a dopamine agonist, if necessary",
"     </li>",
"     <li>",
"      Replace sustained-release levodopa with regular levodopa, if dyskinesia is occurring in the late afternoon and evening",
"     </li>",
"     <li>",
"      Add",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      to counteract dyskinesia (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Amantadine'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Manage diphasic dyskinesia with more frequent levodopa dosing",
"     </li>",
"     <li>",
"      Use middle-of-the-night levodopa or a dopamine agonist to treat early morning \"off\" period dystonia",
"     </li>",
"     <li>",
"      Reduce the levodopa dose intervals or add a dopamine agonist to treat \"off\" period dystonia during the day",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/1\">",
"      Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/2\">",
"      Pappert EJ, Buhrfiend C, Lipton JW, et al. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord 1996; 11:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/3\">",
"      Ahlskog JE, Muenter MD, McManis PG, et al. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 1988; 63:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/4\">",
"      Jankovic J, Schwartz K, Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord 1989; 4:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/5\">",
"      Hutton JT, Morris JL, Rom&aacute;n GC, et al. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa. Arch Neurol 1988; 45:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/6\">",
"      Lieberman A, Gopinathan G, Miller E, et al. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. Eur Neurol 1990; 30:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/7\">",
"      Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/8\">",
"      Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994; 9:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/9\">",
"      Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/10\">",
"      Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/11\">",
"      Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998; 51:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/12\">",
"      Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/13\">",
"      LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/14\">",
"      Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 2011; 77:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/15\">",
"      LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/16\">",
"      Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997; 49:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/17\">",
"      Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/18\">",
"      Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 1998; 13:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/19\">",
"      Clarke CE, Deane KD. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001; :CD001519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/20\">",
"      Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/21\">",
"      Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/22\">",
"      Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/23\">",
"      Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004; 21:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/24\">",
"      Steiger MJ, El-Debas T, Anderson T, et al. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996; 243:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/25\">",
"      Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996; 19:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/26\">",
"      Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006; 67:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/27\">",
"      Nutt JG. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 1998; 351:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/28\">",
"      Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the \"wearing-off\" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/29\">",
"      Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the \"wearing off\" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/30\">",
"      Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997; 42:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/31\">",
"      Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/32\">",
"      Brooks DJ, Sagar H, UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003; 74:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/33\">",
"      Watkins P. COMT inhibitors and liver toxicity. Neurology 2000; 55:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/34\">",
"      Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/35\">",
"      Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988; 11:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/36\">",
"      Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/37\">",
"      Pierantozzi M, Pietroiusti A, Galante A, et al. Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients. Ann Neurol 2001; 50:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/38\">",
"      Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006; 66:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/39\">",
"      Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003; 61:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/40\">",
"      Hauser RA, Hubble JP, Truong DD, Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003; 61:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/41\">",
"      Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008; 70:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/42\">",
"      Nutt JG, Woodward WR, Hammerstad JP, et al. The \"on-off\" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/43\">",
"      Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992; 49:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/44\">",
"      Riley D, Lang AE. Practical application of a low-protein diet for Parkinson's disease. Neurology 1988; 38:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/45\">",
"      Espay AJ, Dwivedi AK, Payne M, et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 2011; 76:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/46\">",
"      Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012; 11:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/47\">",
"      Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology 2005; 64:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/48\">",
"      Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clin Neuropharmacol 2003; 26:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/49\">",
"      Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/50\">",
"      Jost WH. Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 1997; 10:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/51\">",
"      Drolet B, Rousseau G, Daleau P, et al. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000; 102:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/52\">",
"      Quinn N. Drug treatment of Parkinson's disease. BMJ 1995; 310:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/53\">",
"      Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/54\">",
"      Van Gerpen JA, Kumar N, Bower JH, et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006; 63:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/55\">",
"      Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003; :CD003467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/56\">",
"      Luginger E, Wenning GK, B&ouml;sch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000; 15:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/57\">",
"      Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/58\">",
"      Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/59\">",
"      Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/60\">",
"      Durif F, Vidailhet M, Assal F, et al. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997; 48:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/61\">",
"      Bennett JP Jr, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/62\">",
"      Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004; 62:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/26/18857/abstract/63\">",
"      Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000; 55:795.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4893 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18857=[""].join("\n");
var outline_f18_26_18857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WEARING-OFF PHENOMENON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Alteration of levodopa dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Addition of a second drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dopamine agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - COMT inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - MAO B inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Guideline recommendations for treating \"off\" time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      UNPREDICTABLE OFF PERIODS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ACUTE AKINESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FAILURE OF ON-RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DYSKINESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Amantadine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clozapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Guideline recommendations for reducing dyskinesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DYSTONIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Wearing \"off\" phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Unpredictable \"off\" periods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Failure or delay of the \"on\" response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dyskinesia and dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/8/34947?source=related_link\">",
"      Patient information: Medicines for Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=related_link\">",
"      Surgical treatment of Parkinson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_26_18858="H pylori gastritis Light";
var content_f18_26_18858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1110px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Helicobacter pylori gastritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a gastric biopsy obtained at endoscopy shows infiltration of glands with neutrophils (arrow) and increased mononuclear cell infiltration typical of Helicobacter pylori gastritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Normal gastric antrum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Normal surface (SE) and foveolar epithelium (FE) and glands (G). Right panel: Higher power view of the glands shows mucous cells (M) and gastrin-secreting endocrine cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18858=[""].join("\n");
var outline_f18_26_18858=null;
var title_f18_26_18859="Warning signs for serious causes of back pain in children";
var content_f18_26_18859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Warning signs of potentially serious causes of back pain in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Young age: prepubescent, especially before school-age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constant pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Night pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progression of symptoms over time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant pain or disability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sciatica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repetitive microtrauma, especially lumbar hyperextension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of exposure to tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel or bladder symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal neurologic examination: asymmetric reflexes, Babinski, low rectal tone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18859=[""].join("\n");
var outline_f18_26_18859=null;
var title_f18_26_18860="Mechanical vent in BP fistula";
var content_f18_26_18860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for ventilator management in the patient with bronchopleural fistula",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Reduce both mean airway pressure and the number of",
"positive-pressure breaths, using the lowest number of mechanical",
"breaths that permits acceptable alveolar ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Wean patient completely if possible&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Partial ventilatory support (eg, low-rate SIMV or pressure support) is preferable to total ventilatory support (eg, assist/control, high-rate SIMV, or pressure control ventilation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Avoid or correct respiratory alkalosis (to minimize minute ventilation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Consider use of permissive hypercapnia (reducing minute ventilation and allowing arterial PCO2 to rise)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit effective (returned) tidal volume to 5 to 8 mL/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Minimize inspiratory time, and hence mean airway pressure:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Keep inspiration-to-expiration ratio low (eg, 0.33)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Use high inspiratory flow rate (eg, 70 to 100 L/min)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Avoid inflation hold (end-inspiratory pause) and inverse-ratio ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Use low-compressible-volume (non-disposable) ventilator circuit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimize PEEP (both dialed-in and auto-PEEP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use least amount of chest tube suction that maintains lung inflation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If spontaneous movement exacerbates leak, keep patient",
"heavily sedated (in unusual circumstances muscle relaxation may also be",
"necessary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Explore position differences, and avoid patient positions that increase the leak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat bronchospasm and other causes of expiratory airflow obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider specific or unconventional measures (eg, independent",
"lung ventilation, high-frequency jet ventilation, PEEP to chest tubes,",
"etc) only if the air leak per se is clinically felt to be worsening the",
"patient's condition (eg, intractable hypotension or arrhythmias in",
"association with respiratory acidosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat underlying cause of respiratory failure, maintaining",
"nutritional and other support, with goal of discontinuing mechanical",
"ventilation as soon as possible",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18860=[""].join("\n");
var outline_f18_26_18860=null;
var title_f18_26_18861="Sources of iodine";
var content_f18_26_18861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Iodine content of some iodine-containing medications and radiographic contrast agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Substance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amount of iodine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Potassium iodides (thyroprotectant and prethyroidectomy agents)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potassium iodide oral tablet",
"       </td>",
"       <td>",
"        50 mg iodine per 65 mg potassium iodide tablet; 100 mg iodine per 130 mg potassium iodide tablet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potassium iodide oral solution",
"       </td>",
"       <td>",
"        50 mg iodine per mL of 65 mg/mL potassium iodide solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potassium iodide oral saturated solution (SSKI)",
"       </td>",
"       <td>",
"        770 mg iodine per mL (&asymp;20 drops) of 1000 mg/mL potassium iodide saturated solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potassium iodide and iodine mixture (Lugol solution, Strong iodine solution)",
"       </td>",
"       <td>",
"        Total 127 mg iodine per mL (&asymp;20 drops) of 100 mg/mL potassium iodide and 50 mg/mL iodine mixture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Antiarrhythmic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amiodarone",
"       </td>",
"       <td>",
"        75 mg iodine per 200 mg amiodarone*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Radiographic preparations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iodinated contrast agents",
"       </td>",
"       <td>",
"        Significant source of short-term iodine exposure. Typical oral preparations may contain 300 to 480 mg iodine per mL or tablet.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intravenous preparations",
"       </td>",
"       <td>",
"        140 to 400 mg/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Topical antiseptic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Povidone-iodine solution 10 percent",
"       </td>",
"       <td>",
"        10 mg iodine per mL solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iodine tinctures 2 and 7 percent",
"       </td>",
"       <td>",
"        20 mg iodine per mL of 2 percent tincture; 70 mg iodine per mL of 7 percent tincture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cadexomer-iodine dressings, ointment, powder, paste",
"       </td>",
"       <td>",
"        9 mg iodine per gram of cadexomer-iodine ointment, powder or paste",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iodoquinol cream 1 percent",
"       </td>",
"       <td>",
"        6.4 mg iodine per gram of 1 percent cream (preparation may include 1 or 2 percent hydrocortisone)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clioquinol cream",
"        <sup>",
"         &bull;",
"        </sup>",
"        3 percent",
"       </td>",
"       <td>",
"        12 mg iodine per gram of 3 percent cream",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Amebicidal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iodoquinol (Yodoxin, Diodoquin)",
"       </td>",
"       <td>",
"        134 mg iodine per 210 mg iodoquinol oral capsule; 415 mg iodine per 650 mg iodoquinol oral capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Douches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Povidone-iodine",
"       </td>",
"       <td>",
"        10 mg iodine per mL solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Iodine containing expectorants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iodinated glycerol, calcium iodide",
"       </td>",
"       <td>",
"        Iodine has largely been discontinued as an ingredient of expectorants due to safety concerns. Typical preparations formerly available in the US contained approximately 6 to 25 mg iodine per mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Kelp or seaweed containing supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oral kelp (wrack, bladderwrack)",
"       </td>",
"       <td>",
"        Up to 6 mg of iodine may be contained in a 600 mg serving of kelp",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cellasene (anti-cellulite supplement)",
"       </td>",
"       <td>",
"        720 mcg of iodine per serving",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Approximately 10 percent is released as free inorganic iodine. Accumulation of amiodarone in body tissue results in a prolonged iodine exposure half-life (months or more) after discontinuation.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Clioquinal cream is not available as a single ingredient or combination product in the US. It is available in combinations with flumethasone as a topical cream and as otic in Canada.",
"      <br>",
"       &Delta; Iodine content is variable due to variability in source kelp and preparation.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18861=[""].join("\n");
var outline_f18_26_18861=null;
var title_f18_26_18862="Steady state response to K load";
var content_f18_26_18862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Response to potassium load",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 270px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Response to increasing potassium intake from 100 to 400 meq/day in normal subjects. Urinary potassium excretion rises to over 300 meq/day within two days, a response that is driven by increases in both aldosterone release and the plasma potassium concentration. By day 20, potassium excretion is almost 400 meq/day, the plasma aldosterone level is near normal, and there is only a small rise in the plasma potassium concentration to 4.2 meq/L.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rabelink TJ, Koomans HA, Hen&eacute; RJ,&nbsp;et al.&nbsp;Kidney Int 1990; 38:942.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18862=[""].join("\n");
var outline_f18_26_18862=null;
var title_f18_26_18863="2D TTE Parasternal short axis LV papillary muscles";
var content_f18_26_18863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view showing the papillary muscles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short axis image was taken at the same level of the minor axis of the left ventricle (LV); the posteromedial (PMPM) and anterolateral papillary muscles (ALPM) can be seen. The cut through the posteromedial papillary muscle is closer to its tip than the one through the anterolateral.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_26_18863=[""].join("\n");
var outline_f18_26_18863=null;
      